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I. PRD Risk Title: Risk of Acute Radiation Syndromes due to Solar Particle 
Events 
 
Crew health and performance may be impacted by a major solar particle event (SPE), multiple 
SPEs, or the cumulative effect of galactic cosmic rays (GCR) and SPEs. Beyond low-Earth orbit, 
the protection of the Earth's magnetosphere is no longer available, such that increased shielding 
and protective mechanisms are necessary in order to prevent acute radiation sickness and impacts 
to mission success or crew survival. While operational monitoring and shielding are expected to 
minimize radiation exposures, there are EVA scenarios outside of low-Earth orbit where the risk 
of prodromal effects, including nausea, vomiting, anorexia, and fatigue, as well as skin injury and 
depletion of the blood-forming organs (BFO), may occur.  There is a reasonable concern that a 
compromised immune system due to high skin doses from a SPE or due to synergistic space flight 
factors (e.g., microgravity) may lead to increased risk to the BFO. The primary data available at 
present are derived from analyses of medical patients and persons accidentally exposed to acute, 
high doses of low-linear energy transfer (LET) (or terrestrial) radiation. Data more specific to the 
space flight environment must be compiled to quantify the magnitude of increase of this risk and 
to develop appropriate protection strategies. In particular, information addressing the distinct 
differences between solar proton exposures and terrestrial exposure scenarios, including radiation 
quality, dose-rate effects, and non-uniform dose distributions, is required for accurate risk 
estimation.  
 
II. Executive Summary 
 
The foundation of acute radiation syndrome (ARS) evidence is ground-based observations 
of humans who were exposed to high levels of ionizing radiation, in particular to gamma- or x-
rays, in a short period of time. Data on ARS have been summarized in the literature and in 
numerous committee reports, including reports from the National Council on Radiation Protection 
(NCRP) and the National Research Council (NRC), which provide the foundation of evidence used 
by NASA for research plans and operational radiation protection strategies. 
 The risk of ARS from exposure to large solar particle events (SPEs) during space missions 
was identified during the early days of the human space program (NAS/NRC 1967). ARS symptoms 
can include hematopoietic, gastrointestinal, cutaneous, and neurovascular decrements. However, the 
ARS symptoms that appear in the prodromal phase post-exposure (e.g., nausea, vomiting, 
anorexia, and fatigue) are the most likely to be experienced based on estimated organ doses 
during extra-vehicular activity (EVA; free space or lunar operations) and could significantly 
impact mission success if adequate shielding is not reached in a timely manner (ICRP 2012). 
Small- to medium-sized SPEs are known to occur quite often over the approximately 11-
year solar cycle, but they are highly episodic and difficult to predict. Large mission-threatening 
events are rare. SPEs include low- to medium-energy protons, with the energy region of most 
importance to human spaceflight extending out to a few hundred MeV, as well as much smaller 
components of helium and heavy nuclei. During such events, the flux of protons with energy 
greater than 10 MeV may increase over background by 4 to 5 orders of magnitude for a period of 
several hours to a few days.  The shapes of the energy spectra, as well as the total fluence, vary 
considerably from event to event. ARS has been well-defined for gamma- and X-ray exposures, 
both characterized as low-LET radiation. However, less is known about the acute effects from 
whole-body exposures to SPE protons, which are characterized by dynamic changes in energy 
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distribution, leading to dose rates that can vary several-fold between tissue sites throughout the 
human body. Additional radiobiology research is needed to understand how reduced immunity from 
large skin doses or other synergistic effects of spaceflight, such as microgravity, may alter dose 
thresholds for response as well as to identify and validate  the effectiveness of medical 
countermeasures for proton irradiations. 
Improvements in SPE forecasting and alert systems are needed to minimize operational 
constraints, especially for EVA. While radiation shielding is an effective mitigation to ARS, the 
high cost of shielding requires accurate estimates of the risk to ensure that sufficient protection is 
provided without overestimating shielding requirements.   
NASA has developed several models for the probabilistic risk assessment of acute radiation 
syndrome from SPEs. These models include the improved spectral fit of SPEs over all energies 
and the analysis of any SPEs at a certain proton fluence based on the distribution of total fluence 
of the recorded SPEs. These models were built to fulfill National Research Council (NRC) 
recommendations from 2008 for the development of probabilistic approaches to modeling SPEs, 
Managing Space Radiation Risk in the New Era of Space Exploration (NRC 2008). In addition, 
nonlinear kinetics models of bone marrow stem cells and various blood system components have 
been developed to describe and provide accurate descriptions of human and other species 
responses to acute and chronic irradiation. These organ dose projection models are incorporated 
in a software package called ARRBOD for use by mission planners, radiation shield designers, 
and space operations to evaluate clinically significant deterministic health effects, including 
performance degradation in flight, from exposure to large SPEs.  
 
 
III. Introduction 
 
A. Description of Acute Risks of Concern to NASA 
 
In contrast to the constant presence of GCRs in space, SPE exposures are sporadic and occur 
with little warning. During a SPE, the Sun releases a large amount of energetic particles. Although 
the composition of the particle type varies slightly from event to event, those of most concern for 
human missions on average consist of 96% protons, 4% helium ions, and a small fraction of heavier 
ions (NCRP 1989a; Cucinotta et al. 1994; Townsend et al. 1994; Kim et al. 1999). The intensity and 
the energy spectrum of an SPE vary throughout the course of the event, which lasts from a few 
hours to several days. Each event has distinct temporal and energy characteristics. The intensity 
of the event can be described by particle fluence, F>E, which is the number of ions per unit area 
with energy greater than E, expressed as mega electron volts per nucleon (MeV/n). The energies 
of the protons are important because the range of penetration of these protons increases with energy. 
Protons with energies above 30 MeV have sufficient range to penetrate an EVA spacesuit and are 
used as a simple scaling parameter to compare different SPEs. The majority of SPEs observed 
in the last 50 years are relatively harmless to human health, with doses below 10 mGy requiring 
minimal shielding protection. However, SPEs that have the highest fluence of particles with 
energies above 30 MeV are of greatest concern for future missions outside the protection of the 
earth’s magnetic field (Kim et al. 2011). 
 Figure 1 shows data that were collected in the modern era for the F>30 MeV proton fluence 
(bottom panel) from large SPEs and the solar modulation parameter (Φ) (upper panel). The solar 
modulation parameter describes the strength of the sun’s magnetic field with solar maximum at 
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Φ>1,000 MV (Kim et al. 2011). The various SPEs shown in Figure 1, which are characterized as 
large SPEs (F>30 MeV > 10
8 particles/cm2), would contribute doses of 10 to 500 mGy for average 
shielding conditions. Although the dose resulting from the majority of SPEs is small, SPEs 
nonetheless pose significant operational challenges because the eventual size of an event cannot 
be predicted until several hours after the particles are initially detected. Extraordinarily large SPEs 
were recorded in November 1960, August 1972, and October 1989. In general, SPEs occur more 
often near solar maximum, but as Figure 1 shows, the correlation between event frequency and 
solar conditions is not precise (Shea and Smart 1990; Kim et al. 2011). To date, accurate short- or 
long-term prediction of SPEs has not been possible. 
 
 
Figure 1. Historical data on fluence of protons above 30 MeV per cm2 (F>30 MeV from large SPEs relative 
to solar modulation parameter [Φ]). Only events with F>30 MeV >108 protons/cm2 are shown. 
 
Without sufficient shielding protection for these large events, a whole-body dose of over 0.5 
Gy (500 mGy) may be received over a period of several hours (Parsons and Townsend 2000; Kim 
et al. 2011), which would put humans at risk for development of ARS and could impact operations 
by affecting crew performance, leading to the possibility of mission failure. However, shielding 
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and operational, active dosimetry are effective countermeasures to SPEs inside spacecraft, making 
ARS extremely unlikely except in extended EVA or combined EVA and intra-vehicular activity 
(IVA) scenarios (Wilson 1997). 
 
B. Current NASA Permissible Exposure Limits 
 
Current permissible exposure limits (PELs) for short-term and career astronaut exposures 
to space radiation have been approved by the NASA Chief Health and Medical Officer as 
documented in NASA Standard 3001, Vol. 1, Revision A, 2014. The PELs provide the basis for 
setting requirements and standards for mission design and crew selection. Past reviews of evidence 
by the National Academy of Sciences (NAS) and the NCRP form the basis for the NASA PELs, 
including short-term limits that are imposed to prevent clinically significant deterministic health 
effects, including performance degradation in flight (NASA 2007, 2011, 2014). NAS first 
reviewed space flight issues in 1967 (NAS/NRC 1967) and conducted a further review in 1970 
(NAS/NRC 1970) that led to the dose limits that were used at NASA until 1989. Extensive reviews 
of humans and experimental radiobiology data for ARS were provided to NASA by reports of the 
NCRP in 1989, 2000, and 2006 (NCRP 1989b, 2000, 2006). The report of the NAS in 1970 is the 
basis for the limits to the BFO that are currently used at NASA, which are instituted to protect the 
hematopoietic system from depletion below a critical limit. Dose limits for the prodromal risks 
were not advocated by the NAS or the NCRP for NASA missions in the past. However, the BFO 
limit likely occurs at doses below that of the threshold for prodromal effects, so adherence to the 
BFO 30-day limit protects against occurrence of ARS. 
The current NASA dose limits for deterministic effects to the lens, skin, BFO, and 
circulatory system, which are given in units of Gray-equivalent (Gy-Eq), are listed in Table 1. 
The unit of Gray-equivalent is calculated using the relative biological effectiveness (RBE) values 
shown in Table 2 as described in NCRP Report No. 132 (2000) and is distinct from the unit of 
Sievert (Sv) that is used to project cancer risk. Note that while the Gray Equivalent quantity is used 
to limit these non-cancer effects (Table 1), the RBEs for central nervous system (CNS) non-cancer 
effects are largely unknown; therefore, a physical dose limit (mGy) is used, with an additional PEL 
requirement for particles with charge Z>10 (Table 1). 
Doses to the BFO from an SPE event above 1 Gy are highly unlikely if crew members are 
able to reach a moderately shielded (5 to 10 g/cm2) location in a timely manner.  Table 3, updated 
from Hu et al. (2009) using ARRBOD 2.0 with an exponential fitting scheme, presents estimates 
of several dosimetric quantities from three historically large SPEs (August 1972 SPE, October 
1989 SPE, September 1989 SPE) for the total event spectra in interplanetary space calculated for 
a spacesuit during an EVA (an aluminum sphere of 0.3 gm/cm2 thickness), inside a typical 
equipment room of a spacecraft (an aluminum sphere of 5 gm/cm2 thickness) and with increasing 
quantities of shielding. These are total dose estimates over an entire event spectra, which exceeded 
60 hrs for the August 1972 event. 
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Table 1. Dose Limits for Short-Term or Career Non-Cancer Effects (in mGy-Eq or mGy) 
Note: RBEs for specific risks are distinct as described below. 
Organ 30-day limit 1-year limit Career 
Lens* 1,000 mGy-Eq 2,000 mGy-Eq 4,000 mGy-Eq 
Skin 1,500 mGy-Eq 3,000 mGy-Eq 6,000 mGy-Eq 
BFO 250 mGy-Eq 500 mGy-Eq Not applicable 
Heart** 250 mGy-Eq 500 mGy-Eq 1,000 mGy-Eq 
CNS*** 500 mGy 1,000 mGy 1,500 mGy 
CNS*** (Z ≥ 10) – 100 mGy 250 mGy 
 
*Lens limits are intended to prevent early (<5 yr) severe cataracts, e.g., from a solar particle event. An additional 
cataract risk exists at lower doses from cosmic rays for sub-clinical cataracts, which may progress to severe types 
after long latency (>5 yr) and are not preventable by existing mitigation measures; however, they are deemed an 
acceptable risk to the program.  
**Circulatory system doses calculated as average over heart muscle and adjacent arteries.  
***CNS limits should be calculated at the hippocampus.  
Reference: NCRP (2000) Recommendations of Dose Limits for Low Earth Orbit. NCRP Report 132, Bethesda MD.  
 
 
Table 2. RBE for Non-Cancer Effectsa of the Lens, Skin, BFO, and Circulatory Systems 
 
a RBE values for late deterministic effects are higher than for early effects in some tissues and are influenced by the 
doses used to determine the RBE.  
b There are not sufficient data on which to base RBE values for early or late effects by neutrons of energies <1 MeV 
or greater than about 25 MeV.  
c There are few data on the tissue effects of ions with a Z>18, but the RBE values for iron ions (Z=26) are 
comparable to those of argon (Z=18). One possible exception is cataract of the lens of the eye because high RBE 
values for cataracts in mice have been reported.  
Reference: NCRP (2000) Recommendations of Dose Limits for Low Earth Orbit. NCRP Report 132, Bethesda MD. 
 
 
Table 3. Dosimetry quantities in interplanetary space from total event spectra of three large SPEs. (Note: 
EVA exposures (0.3 gm/cm2) listed in Table are highly unlikely and illustrate the effectiveness of 
operational protocols where crew would shelter for the majority of event duration which can last for 
several days.) 
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Tissue-specific dose estimates for females and males (in Gy) for the August 1972 King event are 
presented in Table 4. These numbers were generated using Oltaris (https://oltaris.nasa.gov/) with 
FAX and MAX anatomical models. The GI dose is computed as the average dose received by the 
small intestine, stomach, and colon. Note the rapid attenuation of tissue dose with increasing 
quantities of shielding. Design and operational requirements, including access to storm shelters 
with thicker shielding, will aim to minimize exposures to less than 250 mGy-Eq to the BFO, thus 
limiting health risks to the crew. 
 
 
Table 4. Total tissue dose accumulation for the August 1972 SPE calculated using the Oltaris web-based 
analysis tool. (Note: EVA exposures (0.4 gm/cm2) listed in Table are highly unlikely and illustrate the 
effectiveness of operational protocols where crew would shelter for the majority of event duration which 
can last for several days.)  
 
 
 
Shielding Thickness 0.4 g/cm2 5 g/cm2 10 g/cm2 20 g/cm2 0.4 g/cm2 5 g/cm2 10 g/cm2 20 g/cm2
Organ Specific Dose 
(Gy)
Skin 27.98 2.74 0.71 0.11 28.20 2.76 0.72 0.11
BFO 1.43 0.39 0.14 0.03 1.01 0.29 0.11 0.03
Brain 1.55 0.51 0.20 0.05 1.30 0.45 0.17 0.04
Hippocampus 1.04 0.38 0.15 0.04 0.92 0.34 0.14 0.04
Ovaries 0.28 0.12 0.06 0.02 3.95 0.92 0.30 0.06
GI 0.63 0.23 0.09 0.03 0.49 0.19 0.08 0.02
Small_Intestine 0.57 0.21 0.09 0.02 0.44 0.17 0.07 0.02
Stomach 0.53 0.20 0.09 0.02 0.49 0.19 0.08 0.02
Colon 0.81 0.28 0.11 0.03 0.54 0.20 0.08 0.02
Adrenals 0.26 0.11 0.05 0.02 0.14 0.07 0.04 0.01
Bladder 0.37 0.15 0.06 0.02 0.36 0.14 0.06 0.02
Bone 2.27 0.56 0.20 0.04 1.75 0.45 0.16 0.04
Breast 4.08 1.02 0.34 0.06 1.31 0.41 0.15 0.04
Esophagus 0.53 0.21 0.09 0.03 0.42 0.17 0.08 0.02
Heart 0.44 0.18 0.08 0.02 0.60 0.23 0.10 0.03
Kidneys 0.43 0.17 0.08 0.02 0.33 0.14 0.06 0.02
Lens 10.76 1.85 0.54 0.09 12.57 1.82 0.52 0.09
Liver 0.67 0.24 0.10 0.03 0.44 0.17 0.07 0.02
Lungs 1.74 0.55 0.20 0.05 0.94 0.33 0.13 0.03
Muscle 1.98 0.57 0.20 0.04 1.91 0.55 0.20 0.04
Pancreas 0.26 0.11 0.05 0.02 0.15 0.07 0.04 0.01
Retina 3.27 0.87 0.29 0.06 0.27 0.11 0.05 0.02
Salivary_Glands 5.99 1.13 0.35 0.06 2.74 0.76 0.26 0.05
Spleen 0.68 0.25 0.10 0.03 5.94 1.09 0.34 0.06
Thymus 1.51 0.48 0.18 0.04 0.52 0.20 0.08 0.02
Thyroid 2.39 0.64 0.22 0.05 0.51 0.20 0.09 0.03
Trachea 1.44 0.45 0.17 0.04 1.18 0.38 0.14 0.03
Uterus 0.23 0.10 0.05 0.02 1.05 0.35 0.14 0.03
Female Male
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IV. Evidence 
 
A. Human Evidence 
 
The human evidence presented in this section is Category III unless otherwise noted.   
 
1.  Reviews of Human Data in Patients and Accident Victims 
 
ARS involves exposure to high doses of radiation received over a large portion of the body 
in a very short window of time. Scenarios where this type of exposure could occur include nuclear 
power plant accidents, mishaps with irradiations used for sterilization purposes, military personnel 
in the event of a nuclear bomb detonation, and the general population should a terrorist attack 
occur that involves nuclear devices (Waselenko et al. 2004; Pellmar et al. 2005). Evidence of ARS 
in humans from low-LET radiation, such as gamma- or X-ray exposures, has been thoroughly 
reviewed and documented in the reports that have been generated by regulatory bodies such as the 
NAS, the National Council on Radiation Protection (NCRP), the International Commission on 
Radiological Protection (ICRP), the National Research Council (NRC), and the U.S. Nuclear 
Regulatory Commission (NAS/NRC 1967; NCRP 1982, 1989a, 1993, 2000; Baum et al. 1984; Evans 
et al. 1985;ICRP 2000, 2002, 2012; NRC 2008) (Category IV). Data accumulated over the last half-
century that were used in the construction of the dose threshold for ARS were derived from the 
following studies: studies on the Japanese atomic bomb survivors (Ishida and Matsubayashi 1948; 
Ohkita 1975;Oughterson and Warren 1956), case studies of nuclear accident victims (Blakely 
1968; Vodopick and Andrews 1974;Gilberti 1980), and records of total-body irradiated therapy 
patients for cancer and other diseases (Adelstein and Dealy 1965;Brown 1953; Warren and Grahn 
1973).  More recent events include the Chernobyl accident in 1986 (Bouville et al. 2006), an accident 
that occurred in Tokai-mura, Japan, in 1999 (Hirama et al. 2003), and the death of a Russian 
citizen after a possible internal overdose of radioactive materials as reported in the media in 2006.  
ARS appears in various forms and has different threshold doses for onset of the possible 
effects. A previous definition of the threshold dose consisted of an exposure below which clinically 
significant effects do not occur (NCRP 2000). However, the ICRP has recently redefined a 
threshold dose as the dose required to cause a 1% incidence of an observable effect (ICRP 2007, 
2012). 
Radiation exposure induces physiological responses in many organ systems such as the 
hematopoietic, immune, reproductive, circulatory, respiratory, musculoskeletal, endocrine, 
nervous, and digestive systems, as well as the urinary tract, skin, and eye. However, the early 
effects (from the first hours to several weeks after exposure) are mainly manifested in the 
hematopoietic, cutaneous, gastrointestinal, and neurovascular systems (ICRP 2012). The 
threshold whole-body dose for ARS is approximately 0.1 to 0.2 Gy for radiation that is delivered 
under acute conditions where dose rates exceed 1 Gy/hr (ICRP 2012). At lower dose rates, a 
reduction in effects (which are described below) is seen. People at the extremes of age (children < 12 
years and adults > 60 years) may be more susceptible to irradiation and have a lower LD50/60 (Hall 
2006) 
Doses that are in the range of 0.5 to 1 Gy cause minor acute damage to the hematopoietic 
system and mild prodromal effects (nausea, vomiting, anorexia, and fatigue) in a small number of 
irradiated persons (Anno et al. 1989). In the acute dose range of 1 to 2 Gy, prodromal effects and 
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injury to the hematopoietic system increase significantly; however, most victims will probably 
survive, with only 5% lethality in a population after doses of about 2 Gy (NAS/NRC 1967; 
McFarland and Pearson 1963). Survival is also possible within the dose range of 2 to 3.5 Gy, but 
prodromal effects become more pronounced, decreasing in latency and increasing in severity. As 
the dose reaches about 3.25 Gy, 50% of exposed people may die within 60 days if appropriate 
medical care is not administered (Lushbaugh 1969). From 3.5 to 5.5 Gy, symptoms are even more 
severe and affect nearly all who are exposed. If untreated, 50% to 99% of those who are exposed 
may die primarily because of extensive injury to the hematopoietic system that is manifested by 
overwhelming infections and bleeding (NAS/NRC 1967; Lushbaugh 1969; Messerschmidt 1979). 
At this dose range, permanent sterility occurs in both males and females (Paulsen 1973; NCRP 
1989a).   
Responses to doses between 5.5 and 7.5 Gy begin to reflect the combined effects of gastro-
intestinal and hematopoietic damage. Survival is almost impossible without a compatible bone 
marrow transplant and/or extensive medical care. Nearly everyone who is irradiated at these doses 
suffers severe prodromal effects during the first day after exposure. When doses range between 
7.5 and 10 Gy, injuries are much more severe due to a greater depletion of bone marrow stem cells 
(Adelstein and Dealy 1965; Lushbaugh 1962), increased gastrointestinal damage, and systemic 
complications from bacterial endotoxins entering the blood system. 
Doses that are between 10 and 20 Gy produce early post-exposure renal failure (Lushbaugh 
1974). Death results in fewer than 2 weeks from septicemia due to severe gastrointestinal injury, 
which is complicated by complete bone marrow damage and the cessation of granulocyte produc-
tion (Lushbaugh, 1962). Above approximately 13 Gy, death may occur sooner from electrolyte 
imbalance and dehydration due to vomiting and diarrhea, especially in hot and humid conditions. 
Extremely severe gastrointestinal and cardiovascular damage causes death within 2 to 5 days after 
doses of 20 to 23 Gy (Lushbaugh 1969). 
 
2. Organ-Specific Manifestations of the Acute Radiation Syndrome  
 
The manifestation of ARS reflects the disturbance of physiological processes of various 
cellular groups damaged by radiation. Hematopoietic cells, skin, intestine, and vascular 
endothelium are among the tissues of the human body most sensitive to ionizing radiation. Most 
ARS effects are directly related to these tissues, as well as the coupled regulation and adaptation 
systems (nervous, endocrine, cardiovascular systems) (Guskova et al. 2001). Four sub-syndromes 
are identified: hematopoietic syndrome, cutaneous syndrome, gastrointestinal syndrome, and 
neurovascular syndrome. It is generally agreed that there are three phases in the development of the 
ARS: the prodromal phase, the latent phase, and the manifest phase. The severity and duration of 
each of these phases are dependent on the dose and dose rate. The prodromal phase refers to the 
first 48 hours after exposure, but it may persist for up to 6 days (Alexander et al. 2007). The 
syndromes are dose-dependent and include hematopoietic depression, gastrointestinal distress 
(nausea, vomiting, and/or diarrhea), and neurological symptoms (including fatigability, weakness, 
headache, impaired cognition, disorientation, ataxia, seizures, and hypotension). The latent phase 
lasts about 2 to 20 days, with a seeming improvement of most syndromes (except cytopenia) and 
duration correlating inversely with the absorbed dose. The manifest phase lasts from 2 to 60 days, 
with signs and symptoms expressed by various organs and profound immune suppression 
predisposing the body to infection and sepsis. This phase is critical for radiation injury. Most 
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patients surviving this phase will recover but are still at risk for intermediate effects such as 
pneumonitis and late effects (NCRP 2006; Guskova et al. 2001).  
Based on the historical record of SPE fluence and likely shielding conditions, the most 
probable ARS effects from SPE exposure during spaceflight that can potentially affect mission 
success are the clinical symptoms associated with the prodromal phase of mild hematopoietic 
syndrome (nausea, vomiting, anorexia, and fatigue) occurring within the first 48 hrs following 
exposure, along with skin injury and depression of the BFOs (NAS/NRC 2006; Wilson et al. 1997). 
In general, symptoms develop within a few hours of radiation exposure and rarely exceed 24 hrs 
following low-LET radiation exposure (Fajardo et al. 2001). Exposure to higher doses results in 
greater severity, early onset, and longer duration of the symptoms (Anno et al. 1996). During 
spaceflight, the potential for a higher dose to the skin with associated changes in immune status may 
occur due to the inhomogeneous dose distribution associated with SPE exposure that may alter the 
threshold dose and time course for ARS. From ground-based observations, it is known that recovery 
from ARS can be hindered by changes in immune status, including those resulting from combined 
skin burns and other trauma (Fliedner et al. 2001). Therefore, understanding the effects of a higher 
skin exposure relative to the BFO on the hematopoietic and immune systems is important, as is the 
potential impact of microgravity and other spaceflight-associated changes to the immune system. 
Significantly smaller amounts of data are available for prodromal effects from continuous 
exposure at lower dose rates. The current knowledge that has been collected from studies on 
victims who were exposed to radioactive fallout following the testing of nuclear devices and to 
other sources (Kumatori et al. 1980; Cronkite et al. 1956) is that dose rates of perhaps less than a 
few tens of mGy/h are probably not sufficient to cause ARS. However, continuous dose rates of 
around 100 mGy/h are probably high enough to cause significant vomiting within a period of 
approximately 1 day. Accordingly, between a few tens of mGy/h to approximately 100 mGy/h, a 
considerable amount of uncertainty exists concerning the human response to continuous radiation 
exposure, which is likely due to variations in the sensitivity of individuals as well as the quality of 
the very limited amount of existing data. 
a. Hematopoietic Syndrome 
Hematopoietic syndrome is characterized by a drop in the number of blood cells, generally 
at doses above 1 Gy to the bone marrow; however, mild symptoms may occur with doses as low 
as 0.3 Gy in susceptible individuals. The effects of radiation on hematopoiesis have been well-
characterized in humans and animals for several decades (Bond et al. 1965). This is due to the 
pioneering work of applying the radiation ablation technique to identify hematopoietic stem cells 
(HSCs) (Till and McCulloch 1961), a small pool of pluripotent cells residing in bone marrow of 
the skeleton. While they have unlimited replication and pluripotent differentiation potential, HSCs 
are very radiosensitive. Their D0 (the dose required to reduce the surviving fraction to 37% of that 
associated with the previous dose) was determined experimentally (in vivo and in vitro) to be 
between 0.6 and 1.6 Gy (Fliedner et al. 2002). Studies on human victims of radiation accidents 
indicate that the hematopoiesis system cannot recover from a traumatic event that kills more than 
99% of these cells and that the resulting damage can only be overcome by a timely transfusion of 
compatible HSCs. On the other hand, lower doses of radiation will leave a sufficient number of 
these self-renewing cells intact, such that complete recovery can be achieved with time (Fliedner 
et al. 2002). 
 13 
The manifestation of the hematopoietic syndrome is different in specific cell lineages. This 
is due to variations in compartment transit times, the mean and ranges of the quantities of mature 
cells in the peripheral blood, and the mean cell lifetimes of different cell lineages.  
Normal human erythrocytes are radioresistant and have a lifespan on the order of 120 days. 
Therefore, even after a complete ablation of all erythropoietic development, the decline of 
erythrocytes in peripheral blood is about 1:120 per day, and after 30 days, the blood erythrocyte 
concentration declines to about 70% of normal values. Therefore, even after moderate- or high-
dose total body irradiation (TBI) or partial body irradiation (PBI), anemia is usually not a 
significant clinical problem (Fliedner et al. 2001). On the other hand, reticulocyte lifespan in blood 
is about 1-3 days, and cell counts after radiation exposure show modulations similar to those of 
granulocytes and other radiosensitive cells. 
Granulocytes are also radioresistant, but they disappear from the blood in a random fashion 
with a half-life of 6.6 hours (Fliedner et al. 2001). A unique feature of granulopoiesis is that a 
reserve pool exists in the bone marrow, where mature granulocytes can stay for a period of time 
depending on the demand in the peripheral blood (Babior and Golde 2001). It is known that the 
total transit time from the stem cell to the mature granulocyte in the marrow is 9–10 days. As 
mature granulocytes are radioresistant, after exposure, the granulocyte concentration in blood does 
not decrease immediately but increases to a magnitude proportional to the absorbed dose in the 
early stage (i.e., granulocytosis). For lethal doses, the granulocytes are completely depleted from 
blood between days 5 and 6; for moderate dose, the granulocyte concentration declines until 
reaching an abortive rise at around day 10, followed by a nadir around days 25-30 and a subsequent 
recovery (Fliedner et al. 2002). The dynamics of granulocyte cell counts in blood after radiation 
exposure reveals the extent of hematopoietic damage (Hu and Cucinotta 2011b). It has been 
established that all types of granulocytes (neutrophils, eosinophils, and basophils) are important to 
provide immune protection to the body. In animal experiments, the time of severe granulopenia is 
closely related to the species-dependent time of lethality (Bond et al. 1965). It is therefore essential 
to provide supportive care to victims to fight infections during the granulopenia period and apply 
techniques such as cytokine and cellular therapies to promote granulocyte proliferation (Singh et 
al. 2012).  
The dynamics of platelets (thrombocytes) in blood after radiation exposure is very similar 
to that of granulocytes. Lethal doses also induce “essentially irreversible” injury to the 
thrombopoietic system and cause declining platelet counts progressively and rapidly to critical low 
levels below 50,000 per mm3 within 10-12 days, which corresponds to the maximum lifespan of a 
platelet. For moderate doses, the pattern of the dynamics of platelets is characterized by a slowly 
declining shoulder lasting 10 to 15 days after exposure, followed by a nadir between 25 and 30 
days and final recovery beyond day 30 and 35 (Fliedner et al. 2002). Thus, the severity and duration 
of thrombopenia are dose-dependent, and a quantitative relationship between platelet counts and 
the absorbed dose of an exposed victim can be established based on previous accidental patient 
data (Smirnova 2012). Reduced platelet counts in patients are clinically manifested by an increased 
tendency for bleeding. Therefore, it is important to provide medical support and therapeutic 
interventions to help patients survive through the period of reduced platelet concentrations.  
Although the average lifespan of a lymphocyte in blood is about 4.4 years (Fliedner et al. 
2002), lymphocytes are the most radiosensitive cell in peripheral blood. A radiation exposure 
resulting in a severe or lethal hematopoietic syndrome is characterized by a marked initial 
lymphocyte depression within the first hours. It has been proposed that this high sensitivity is due 
in part to the migration of lymphocytes from the circulation to lymph tissues and vice versa 
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(Fliedner et al. 2001), or to the radiation-induced apoptosis of mature lymphocytes in peripheral 
blood (Belka et al. 1998). In contrast to other cell lineages, mature lymphocytes recirculate 
between the blood vessels and lymphatic vessels (Gowans 1959). The capillary bed where 
lymphocytes transit from blood to the lymphatic tissue and back to the blood is highly sensitive to 
radiation (Stodtmeister et al. 1956). Due to these characteristics of the lymphopoietic system, 
monitoring the changes in lymphocyte counts after exposure is regarded as the most practical and 
best laboratory test to estimate radiation dose (Dainiak 2002). There are two widely used empirical 
methods for early estimation of the exposed dose after radiation accidents (Blakely et al. 2005). 
Past accidental records indicate that full recovery of normal lymphocyte levels in blood takes 
longer than other cell lineages (Hu et al. 2012). All types of lymphocytes are important components 
of the immune system, and lymphopenia reduces the body’s capability to handle exogenous and 
endogenous cytotoxic agents.  
b. Cutaneous Syndrome 
Cutaneous syndrome describes the complex pathophysiological response of the skin 
following radiation exposure. Skin damage is commonly associated with ARS, but it is also 
possible to receive skin damage without development of ARS from exposure to beta radiation or 
x-rays. The skin epidermis is the outermost surface of the body and functions as a barrier to protect 
from dehydration, mechanical stress, and infections. It undergoes constant turnover through 
continuous self-renewal and differentiation of a small population of epidermal stem cells (Blanpain 
and Fuchs 2009). These underlying proliferative cells are sensitive to radiation and can be injured 
and depleted by high-dose exposures. Radiation damage to skin includes erythema, pigmentation, 
and dry and moist desquamation in the early phase (< 4 weeks) and atrophy and fibrosis (or 
necrosis) in the later phase (> 6 weeks) (NCRP 1989b). The ED10 (dose at which 10% of a 
population exhibits the effect) has been estimated to be 4 Gy for erythema and 14 Gy for the more 
serious moist desquamation (Haskin et al. 1997; Strom 2003). 
Epidermis of all regions is formed with a type of stratified structure. The skin epidermis is 
separated from the underlying dermis by a layer of basement membrane. The maintenance of the 
overall cell population is accomplished by the epidermal stem cells in the basal layer, which can 
both self-renew over their lifespan and differentiate progressively upward to generate multiple 
suprabasal layers. Most cells in the first suprabasal layer are capable of dividing, like the cells in 
the basal layer, and are radiosensitive. The non-dividing cells in the upper layers are 
transcriptionally active but gradually lose cytoplasmic organelles and transit to the outmost stratum 
corneum,  which are essentially dead cells cross-linked by transglutaminase (Fuchs and Horsley 
2008). Though as thin as only several layers of cells (about 40-60 m), these radio-resistant cells 
can significantly reduce the radiation dose across the epidermis, especially for radiation with a 
high -ray component (Fliedner et al. 2001). Investigations indicate that the homeostasis and 
radiation response of the epidermis are delicately controlled by the proliferation kinetics of various 
types of cells as well as the spatial organization of the tissue (Archambeau et al. 1979; Hu and 
Cucinotta 2014). 
During spaceflight, the skin may receive a dose that is up to a magnitude greater than that 
received by internal organs from an SPE during an EVA when minimal protection is available 
(Kim et al., 2006a). Risks of concern include erythema, moist desquamation, and epilation (NCRP 
1989). The ED10 has been estimated to be 4 Gy for erythema and 14 Gy for the more serious moist 
desquamation (Strom 2003; Haskin et al. 1997). Protraction of the exposure increases the dose that 
is required for a given degree of severity by a factor of about 3. The response of the skin depends on 
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the number of exposures, the total dose, the dose per exposure, and the volume of tissue that is 
irradiated (Turesson and Notter 1984). It has been noted that deterministic radiogenic skin injury 
complicates the treatment of many of the high-dose casualties at Chernobyl (Strom 2003). Skin 
doses during an SPE can vary more than five-fold for different regions of the skin due to the steep 
dose gradients that are found in the solar proton energy spectra (Kim et al. 2006a). 
c. Gastrointestinal Syndrome 
The gastrointestinal (GI) system performs many integrated functions, such as absorption 
of fluid and electrolytes, breakdown and absorption of nutrients, and excretion of normal and toxic 
metabolites. The radiosensitivity of this system comes from the epithelial cell lining, which is 
present throughout the entire gastrointestinal tract. These cells undergo constant renewal that 
requires rapid cell turnover. They are thus dependent on the functionality of a pluripotent stem cell 
population localized in the crypts of Lieberkuhn. Exposure to high doses of radiation (> 4 Gy) 
results in the loss of these intestinal crypts and breakdown of the mucosal barrier (Wasalenko et 
al. 2004).   
Early gastrointestinal symptoms include nausea, vomiting, anorexia, and diarrhea, which 
may occur within hours after exposure. Nausea and vomiting may stem from effects on the 
periphery and subsequent stimulation of higher nervous centers or from a response of the CNS. 
However, if these symptoms occur during the first few hours after exposure, the role of the 
central/peripheral nervous system is probably predominant. This is also true for the early onset of 
diarrhea. Early nausea and vomiting are signs of severe exposure, and early diarrhea indicates very 
severe damage that usually leads to death (Conklin and Walker 1987).  
The late symptoms of gastrointestinal syndrome include abdominal cramps and diarrhea, 
which appear 1-2 weeks after exposure. All symptoms relate to a major loss of the stem cell 
population in the crypts and subsequent lack of ability to repopulate and to maintain the epithelial 
barrier (Fliedner et al. 2001). The occurrence of profuse and/or bloody diarrhea is linked to the 
denudation of the GI mucosa as well as to thrombocytopenia due to the impairment of the 
hematopoietic system (see above). This results in increased loss of fluid and electrolytes and 
possible entry and action of enteric (pathogenic and non-pathogenic) bacteria, thus leading to 
infection, dehydration, and electrolyte imbalances that are life-threatening.  
d. Neurovascular or CNS Syndrome 
Even though the CNS is generally considered to be composed of radioresistant tissue, 
exposure to moderate or high doses of radiation can result in a neurovascular syndrome. The CNS 
has higher regulatory control mechanisms, which have been shown to be functionally 
radioresponsive. Abnormal electroencephalograms have been reported following exposure to low-
dose radiation, indicating the disturbance of brain activity (Gangloff 1964). Some symptoms occur 
almost immediately after exposure and include severe nausea, vomiting, diarrhea, disorientation, 
and ataxia.  Within hours following the prodromal period, other symptoms may manifest, including 
headaches, hypotension, and fever; within weeks, neurological and cognitive deficits may become 
evident (Fliedner et al. 2001). The underlying pathophysiology is believed to be related to cerebral 
edema, inflammation, and massive endothelial damage to the microcirculatory system (Fliedner et 
al. 2001; Goans et al. 2012). Supportive care may include antiemetics, antiseizure medications, 
anti-inflammatory agents, mannitol, and furosemide (Feyer et al. 2005, 2014; Goans et al. 2012). 
Symptoms such as nausea, vomiting, and anorexia characterize the prodromal phase of 
ARS and are essential identifying signs for the triage of irradiated persons (Sine et al. 2001). 
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Though these clinical symptoms are expressed by the gastrointestinal system, they are 
physiologically controlled by the CNS (Scarantino 1994). The entire process involves key 
components of the CNS, including areas in the hindbrain and the abdominal vagal afferents. Areas 
in the hindbrain were previously thought of as a vomiting center that controls all afferent impulses 
that can initiate emesis (Wang and Borison 1950). The current concept regarding this coordination 
process is that it is controlled not via an anatomical unit but through a number of loosely organized 
areas within the medulla, which are termed the “central pattern generator” (Hornby 2001). They 
generate efferent signals that are sent to relevant organs and tissues to induce vomiting after 
receiving a stimulus from the dorsal vagal complex located in the dorsal brain stem, which contains 
receptors for several neurotransmitters with potentially important roles in the emetic response. 
These receptors include the neurokinin-1, 5-HT3, and dopamine-2 receptors, which bind to 
substance P, 5-HT, and dopamine, respectively. These neurotransmitters are released from the 
enteroendocrine cells located in the gastrointestinal mucosal of the proximal small intestine once 
exposed to whole-body irradiation or large volume partial body irradiation. They bind to the 
appropriate receptors on the adjacent vagal fibers, leading to an afferent stimulus that terminates 
in the dorsal brain stem. Other sources of afferent input have also been proposed, which include 
the area postrema (Miller and Leslie 1994; Borison 1989) and structures in the limbic lobe, such 
as the amygdala (Zagon et al. 1994; Strominger et al. 1994; Horn et al. 2007).  
Fatigue and weakness are also common syndromes in accident and/or radiotherapy 
patients, and they last much longer than the nausea and vomiting symptoms. They are known to 
be more distressing and can negatively affect cognitive performance, mood, and physical function 
(Curt 2000). There are many factors, acting independently or interactively, that are likely involved 
in the development of fatigue and weakness. Recent research on cancer patients and in animal 
experiments have led to several plausible hypotheses regarding the mechanism of radiation-
induced fatigue and weakness. One hypothesis is that radiation causes an increase in brain 
serotonin (5-HT) levels and/or upreguation of a population of 5-HT receptors, leading to reduced 
somatomotor drive  and working capacity (Andrews et al. 2004). 5-HT has numerous functions, 
including appetite control, sleep, memory, learning, temperature regulation, mood, behavior, 
cardiovascular function, muscle contraction, endocrine regulation, and depression. Its role in 
fatigue development has been verified in investigations of exercise-induced fatigue and chronic 
fatigue syndrome (Ryan et al. 2007). Another potential mechanism of fatigue is related to the 
dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is the central 
regulatory system controlling the release of cortisol, a stress hormone that regulates blood pressure, 
cardiovascular function, carbohydrate metabolism, and immune function. Investigations of breast 
cancer survivors indicated that women who experienced fatigue had significantly lower serum 
cortisol levels than those who did not report fatigue (Bower et al. 2002). Alterations of the HPA 
axis by radiation are evident in previous studies (Schmiegelow et al. 2003). In addition to these 
hypotheses proposed based on clinical and animal studies, vagal afferent nerve activation, 
proinflammatory cytokine dysregulation, and comorbid condition (e.g., anemia, cachexia, 
depression, and sleep disorder) are also suspected to play roles in the development of fatigue (Ryan 
et al. 2007). It is generally accepted that the mechanism of radiation-induced fatigue and weakness 
is multifactorial and involves the dysregulation of several interrelated physiological, biochemical, 
and psychological systems. 
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3. Hereditary and Fertility Effects 
NASA, in past reviews, has included the risks of hereditary, fertility, and sterility effects 
under the discussion of acute radiation risks. Although there is no perfect match of these effects 
with any of the four major radiation risks (acute, cancer, degenerative, and CNS) identified by the 
NASA Human Research Program, based on the past reviews of these effects (NCRP 1989a, 2000), 
they alone are not likely to rise to the level of a major concern. Because SPEs would be the primary 
cause of hereditary and fertility effects, these items are included as part of the acute category of 
risks. 
Comprehensive reviews of the literature regarding heritable genetic risks associated with 
radiation exposure have been published by the United Nations Scientific Committee on the Effects 
of Atomic Radiation (UNSCEAR 2001) and by the Committee to Assess Health Risks from 
Exposure to Low Levels of Ionizing Radiation (NRC 2006). No evidence of hereditary risks has 
been reported from human studies, largely on the children of the victims in Hiroshima and 
Nagasaki (Neel et al. 1990; Nakamura 2006). However, growth retardation and other health effects 
have been reported in the progeny of mice exposed to radiation (Cattanach et al. 1993; Nomura et 
al. 2004). 
For humans, mutations at specific minisatellite loci have also been investigated in the 
children born to parents exposed to radiation (BEIR VII 2006). These loci do not code for proteins, 
and changes in them are not associated with adverse health effects. Studies on the populations 
living in Belarus and Ukraine after the Chernobyl accident, and in the Semipalatinsk nuclear test 
site, have reported increased mutation rates at the loci for estimated parental gonadal doses ranging 
from 20 mSy to 1 Sv (Dubrova et al. 1996; Dubrova et al. 2002). However, other studies on the 
children of Chernobyl clean-up workers and children of A-bomb survivors failed to identify an 
increase in the minisatellite mutation frequency (Livshits et al. 2001; Kodaira et al. 1995). 
Similarly, genetic studies, including investigations of chromosome aberrations, in the offspring of 
A-bomb survivors indicate no effects of radiation from parental exposures (Nakamura 2006). 
Exposure to space radiation may result in reduced sperm counts and changes in other semen 
characteristics. Human germ cells, which include sperm cells and oocytes, are sensitive to 
radiation. Spermatogenesis has been detected in cancer patients who received testicular doses of 
0.2 - 0.8 Gy from scattering radiation (Centola et al. 1994) and in experimental rodents after 
radiation exposures at doses as low as 0.01 Gy (Sapp et al. 1992). A single acute exposure to low-
LET radiation at testes doses of 0.5 Gy could cause temporary sterility, with recovery periods 
dependent on the dose (Yarbro and Perry 1985). Doses above 6 Gy may cause permanent infertility 
(Schover 2005; Meistrich 2013). Testicular damage has also been reported for exposures at low 
dose rates in animal studies (Gong et al. 2014). In a human study, direct comparison of the semen 
characteristics between the health workers occupationally exposed to ionization radiation and the 
control group revealed significant differences in motility characteristics, viability, and 
morphological abnormalities (Kumar et al. 2013).  
Newborn girls have a finite number of about 2 million oocytes, which become reduced 
with increasing age (Ogilvy-Stuart and Shalet 1993). Radiation is known to damage human 
oocytes, with an estimated low-LET dose of 2 Gy to the ovary destroying 50% of immature oocytes 
(Wallace et al. 2003). Women who are older than 40 years at the time of exposure will have a 
smaller pool of remaining oocytes; doses in the range of 4-7 Gy for low-LET radiation may cause 
permanent infertility in this cohort of women from a single exposure (Ogilvy-Stuart and Shalet 
1993). The estimated dose causing permanent sterility in young women exposed chronically is 20 
Gy (Ogilvy-Stuart and Shalet 1993). Temporary or reduced fertility may occur at acute doses as 
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low as 1.25 Gy (Damewood and Grochow 1986). Limited high-LET data indicated greater 
effectiveness of neutrons in inducing apoptosis in the oocytes of female mice (Nitta and Hoshi 
2003). 
Temporary sterility for male astronauts may be the worst potential outcome if the testes 
receive a dose of greater than 0.5 Gy during a SPE. For female astronauts, the doses received 
during a large SPE may cause a reduction of the remaining oocyte number. Whether such a 
reduction will impact the ability to conceive after a mission will depend on the age of the astronaut 
at the time of radiation exposure and other factors such as the dose rate. However, doses to the 
ovaries are estimated to remain well below 0.3 Gy for most shielding configurations and historical 
SPE events (https://oltaris.larc.nasa.gov/). No human data so far have indicated an inheritance of 
diseases from parents exposed to low-LET radiation, and no human data are available for high-
LET radiation. Preserving the germ cells prior to a space mission can reduce any potential 
reproductive or hereditary radiation risks in the astronauts.  
  
B. Ground-based Studies on Acute Radiation Effects 
 
1. RBE and Dose Rate Studies in Mice, Rats, Ferrets, and Larger Species 
 
The data for ARS as a result of exposure to high-LET radiation, e.g., neutrons and heavy 
ions, are collected primarily via animal studies. As mice and rats do not display the prodromal 
effects such as vomiting, limited research on this particular ARS has been performed on ferrets 
using HZE radiation. Rabin et al. (1992, 1994) studied the dose response of 600 MeV/n 56Fe 
ion-induced emesis in ferrets and compared it with the dose response from other radiation types. 
Over the dose range of 0.2 to 0.5 Gy, fission spectrum neutrons and 56Fe ions were more effective 
than 60Co gamma-rays in inducing emesis, and the effects of the 56Fe ions and fission neutrons 
could not be distinguished from each other. 60Co gamma-rays were significantly more effective in 
producing emesis compared with high-energy electrons or 200-MeV protons. The dose rates 
ranged from 0.1 to 1 Gy/min. The relatively large difference in LET between 56Fe ions and fission 
neutrons was not associated with any difference in the effectiveness with which the two types of 
radiation produced emesis. As discussed above, the dose due to high-LET radiation is expected to 
be relatively small.  More recently, animal model systems have been utilized to evaluate acute 
effects from exposure to SPEs including the following biological endpoints related to ARS: 
vomiting (and/or retching) and white blood cell counts in ferrets; white blood cell counts, fatigue, 
and immune system parameters in mice; and skin injury, with accompanying immune system 
changes and white blood cell counts in the Yucatan minipig. In addition, the effects of combined 
exposure to simulated microgravity and space radiation on blood cell counts and immune system 
functions with respect to both the innate immune system and the acquired immune system were 
evaluated in mice (Kennedy 2014). Research focused on characterizing the ARS response in 
animals exposed to SPE-like space radiation as well as the evaluation of known countermeasures 
for these effects.  
For hematopoietic effects, significant decreases in white blood cell counts were observed 
in mice, ferrets, and pigs irradiated at high and low dose rates, ranging from doses of 25-50 cGy 
up to 2 Gy (Ware et al. 2010; Maks et al. 2011; Wilson et al. 2011; Gridley et al. 2011;  Romero-
Weaver et al. 2013; Sanzari et al. 2013a). However, regarding SPE radiation effects on blood cell 
counts, the findings in mice, ferrets, and pigs were not comparable. The RBE values were very 
different in the three species with respect to blood cell counts measured after animal exposure to 
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SPE radiation. The RBE values measured in ferrets and pigs were considerably larger than those 
calculated for mice (Maks et al. 2011; Sanzari et al. 2013c, 2014). For many endpoints in these 
studies, the RBE values increased with lower doses of SPE radiation in the dose ranges evaluated 
(Sanzari et al. 2013e). At doses of 25 cGy to 2 Gy of SPE proton radiation, ferrets had increased 
bleeding times beginning shortly after irradiation. By 13 days after receiving a dose of 2 Gy SPE 
proton, the ferrets had severe clotting abnormalities and many of the irradiated ferrets developed 
symptoms of disseminated intravascular coagulation (Krigsfeld et al. 2012, 2013a, 2013b). This is 
probably due to the significant decline of platelet concentrations in peripheral blood after 
irradiation. 
For neurovascular effects such as vomiting and retching, increases were observed in ferrets 
irradiated at high and low dose rates, starting at doses of 75 cGy and up to 2 Gy (Sanzari et al. 
2013b). Gamma-ray and proton irradiation delivered at a high dose rate of 0.5 Gy/min induced 
dose-dependent changes in the endpoints related to retching and vomiting. The minimum radiation 
doses required to induce statistically significant changes in retching- and vomiting-related 
endpoints were 0.75 and 1.0 Gy, respectively, and the RBE of proton radiation at the high dose 
rate did not significantly differ from 1. Similar but less consistent and smaller changes in the 
retching- and vomiting-related endpoints were observed for groups irradiated with gamma-rays 
and protons delivered at a low dose rate of 0.5 Gy/h. Because this low dose rate is similar to a 
radiation dose rate expected during a SPE, these results suggest that the risk of SPE radiation-
induced vomiting is low and may reach statistical significance only when the radiation dose 
reaches 1 Gy or higher (Sanzari et al. 2013b). 
Several studies analyzed the effects of space radiation alone and combined with modeled 
microgravity on immune system parameters. Alterations in the immune system related to the 
gastrointestinal tract were observed in mice exposed to both gamma-rays and SPE-like proton 
radiation. Irradiated mice exhibited breaks in the intestinal epithelial barrier that allowed the entry 
of bacteria and bacterial products into the circulation and their dissemination in the body (Ni et al. 
2011). These effects appear to be exacerbated when combined with modeled microgravity in 
hindlimb-unloaded animals (Zhou et al. 2012).  
In other studies performed with radiation +/- hindlimb unloading in mice, it was observed 
that the splenic T lymphocyte population is significantly decreased in the irradiated + HU group 
(compared with the non-treated control group). The results also indicated that splenic T cells that 
were isolated and exposed to exogenous activation in the irradiated +/- HU groups had a reduced 
ability to become activated (compared with the results from the HU group and the non-suspended, 
sham-irradiated group) (Sanzari et al. 2013d).  
Acute research studies will provide critical quantitative biological data for the further 
development of probabilistic risk assessment tools. Extrapolation of animal results to humans is 
essential to quantify crew risk. The dose response relationships measured for these endpoints need 
to be compared mathematically with published results for human subjects to approximate the dose 
threshold for an equivalent response in humans in such a way that the predictive value of these 
animal models can be utilized to accurately assess the potential risks to humans in various adverse 
scenarios. Future research will emphasize the likelihood of a compromised immune system due to 
high skin doses from a SPE or due to synergistic space flight factors (e.g., microgravity) and the 
possibility of increased risk to the BFO at relevant doses, evaluating thresholds at and around the 
permissible limits identified in Table 1. 
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2. RBE and Dose Rate Studies of Cell Inactivation 
Because some of the ARS effects are related to cell killing or tissue damage, the RBE and 
dose rate data for cell inactivation by protons can provide insight for understanding ARS resulting 
from SPE exposures (Cucinotta 1999; Yang 1999). Early results of cell inactivation by charged 
particles over a wide range of LET have been reviewed by Ainsworth (1986). In general, the RBE 
for cell inactivation in vitro peaked at an LET of around 100 keV/μm, and the peak RBE value 
varied between 1.5 and 5 for different cell types. The maximum RBE for in vivo responses tended 
to be lower and occurred at a lower LET value compared with the in vitro data. The reported RBE-
LET relationship for in vitro cell killing showed similar trends to those of the early in vivo data 
(Furusawa et al. 2000). 
Factors that determine the dose rate dependence of ARS include: the kinetics of DNA 
repair, apoptosis, cell-repopulation and proliferation, and dose distributions across critical organs. 
Irradiation at lower dose rates is known to reduce the probability of lethality of ARS that is induced 
by low-LET radiation compared with acute irradiation, as illustrated in Figure 2. Differences 
between dose rate effects for protons and X-rays or gamma-rays may occur due to the 
heterogeneous dose contribution from slowing protons or recoil nuclei for SPE organ doses. The 
heterogeneous dose distribution across the bone marrow for protons should lead to a sparing effect 
that complicates comparisons with gamma-rays (where doses are more uniform). The dose 
distribution across the stomach and other organs in the gastrointestinal tract also varies several-
fold for SPEs, which complicates the use of gamma-ray data to predict prodromal risks from SPEs. 
 
 
 
 
Figure 2. Effects of medical treatment and dose rate on the LD50 for gamma radiation and the expected 
region of dose rates for SPEs during EVA (adapted from Haskin et al. 1997). 
 
 
V. Computer-Based Modeling and Simulation 
 
The possible acute health effects to interplanetary crews from large SPEs have previously 
been analyzed by several researchers. To our knowledge, the first evaluation was performed with 
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a lethal-potentially lethal model (Curtis 1986). Another response model developed by the U.S. 
military for nuclear warfare (Jones 1981) was used to investigate the BFO effects after exposure 
of an August 1972 SPE (Wilson et al. 1997). In the following section, some recent efforts in the 
mathematical modeling of ARS in various systems are summarized.  
 
 
A. Radiation-Induced Performance Decrement (RIPD) Models 
  
RIPD radiobiological models were developed by the Defense Nuclear Agency in the 1980-
90s (Anno et al. 1996) with the aim of providing a symptomatology basis for assessing early 
functional impairment of individuals who may be involved in civil defense and various military 
activities in the event of a nuclear attack. These models utilized six sign/symptom (S/S) categories 
of ARS: upper gastrointestinal distress (UG), fatigability and weakness (FW), lower 
gastrointestinal distress (LG), hypotension (HY), infection and bleeding (IB), and fluid loss and 
electrolyte imbalance (FL). In initial work (Anno et al. 1985), the severity of each of these S/S 
categories was described empirically as a function of absorbed dose and time-after-exposure for 
prompt exposures. In later work, physiologically-based models were developed (Anno et al. 1991, 
1996) and incorporated into the RIPD code (Matheson et al. 1995) to estimate the S/S severities 
for protracted exposures. Specifically, the UG model calculates the kinetics of the production and 
metabolic clearing of toxins within bodily fluids, the LG model calculates the cellular kinetics of 
intestinal mucosa, and the FW model calculates the kinetics of lymphocytes and the resulting 
cytokine production. Each model employs a set of differential (rate) equations emulating relevant 
biological processes and containing the radiation dose and/or dose rate as a driving term causing 
damage and/or illness. For each model, a variable such as a toxin level or a cellular population 
level determines the severity of symptoms. The model equations and parameters arise from basic 
research in radiobiology and radiation oncology, with all models adjusted based on the best 
available human data. 
The correlation of incidence as well as severity of various symptoms with exposed dose 
and dose rate was conducted by performing maximum likelihood prohibit analysis of empirical 
data (Anno et al. 1985). While severity is a measure of the effect on a particular individual, 
incidence is a population-based measure of the effect on a certain group, i.e., at some specified 
dose level, and incidence quantifies the proportion of individuals expected to respond according 
to a defined level of severity. The main body of empirical data includes effects of victims of nuclear 
radiation accidents and clinical accounts of cancer patients who received total body irradiation 
therapy from the 1940s to the 1980s. Each S/S category described above was scaled from 1 to 5 
with descriptive levels of increasing severity based on medical records and common clinical 
practice, with Level 1 being normal and Level 5 representing the most severe state of the syndrome 
(Table 5) (Matheson et al. 1995). Then, a temporal response pattern for each syndrome was 
estimated for various ranges of prompt radiation exposure, including the onset, duration, and time-
dependent severity. The protracted irradiation cases were treated similarly with consideration of 
sparing effects due to biological recovery that modify the level of response. 
RIPD models have been applied to assess various ARS effects on astronauts if they 
adversely encountered the August 1972 SPE (Hu et al. 2009). The inside-spacecraft modeling 
starts when the calculated dose rate exceeds 0.1 cGy-eq/h, which is considered by the RIPD 
software as the threshold required to cause human acute effects. From the calculation of the August 
1972 SPE, a male crewmember behind a typical spacecraft shielding (5.0 g/cm2) would have 24 
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hrs of consecutive exposure above this limit (Figure 3). The peak BFO dose rate appeared at the 
7th hour from the onset of organ-sensible flux, with a value of 12.34 cGy-eq/h (Figure 3b). The 
upper gastrointestinal (UG) response has a maximum value of 2.0 at the 16th hour and returns to 
normal after the end of this period (Figure 4). The UG syndrome is quite mild and has a low 
expected incidence of 2% (with 95% confidence limits of 0 to 35%). According to the RIPD 
documentation, only sensitive personnel would exhibit stomach upset, a clammy and sweaty 
feeling, mouth-watering, and frequent swallowing. No vomiting would occur. A peak in 
fatigability and weakness (FW) severity of about 1.6 appears within a few hours after that of UG 
but persists and rises to a level of about 1.8 at 1000 hours. Both levels of severity indicate a rather 
mild FW response. The expected incidence of FW is 17% (with 95% confidence bounds of 3 to 
34%). The low incidence and severity of acute effects indicate that a typical spacecraft shielding 
(5.0 g/cm2) is sufficient to attenuate the SPE of the historical worst case to avoid acute injury to 
male crews (Hu et al. 2009) without seeking shelter in a more heavily shielded storm shelter (10 
to 20 g/cm2). However, the persistence of the mild FW syndrome for such a long time period 
should be of concern for the health of astronauts in the high-risk environment of space.   
 
 
Table 5. Textual descriptions of the symptom severity level and acute radiation syndrome (adapted from 
Matheson et al. 1995). 
Severity 
level 
UG LG FW HY IB FL 
1 No effect No effect No effect No effect No effect No effect 
2 
Upset stomach, 
clammy and 
sweaty, mouth 
waters 
Feels 
uncomfortable 
urge to have 
bowel movement 
Somewhat 
tired, with 
mild 
weakness 
Slightly light-
headed 
Mild fever and 
headache 
Thirsty and has dry 
mouth, weak and 
faint 
3 
Nauseated, 
considerable 
sweating, swallows 
frequently to avoid 
vomiting 
Occasional 
diarrhea 
Tired, with 
moderate 
weakness 
Unsteady upon 
standing quickly 
Joints ache, 
considerable 
sweating, moderate 
fever, no appetite, 
sores in mouth and 
throat 
Very dry mouth and 
throat, headache, 
rapid heartbeat 
4 
Vomited once or 
twice, nauseated, 
and may vomit 
again 
Frequent 
diarrhea, cramps 
Very tired 
and weak 
Faints upon 
standing quickly 
Shakes, chills, and 
aches all over, 
difficult to stop any 
bleeding 
Extremely dry 
mouth, throat, and 
skin, very painful 
headache, difficult 
to move, short of 
breath, burning skin 
and eyes 
5 
Vomited several 
times, including the 
dry heaves, 
severely nauseated, 
and will soon vomit 
again 
Uncontrollable 
diarrhea and 
painful cramps 
Exhausted, 
with almost 
no strength 
In shock, 
breathing rapidly 
and shallowly, 
motionless, skin 
cold, clammy and 
very pale 
Delirious, 
overwhelming 
infections, cannot 
stop any bleeding 
Prostrate 
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Figure 3. The skin and BFO dose rates within a spacesuit during EVA (0.3 g/cm2) (a) and inside a spacecraft 
(5.0 g/cm2) (b). The unit is cGy/h for the skin dose rate and cGy-eq/h1 for the BFO dose rate (Hu et al. 
2009). 
 
 
Figure 4. Acute response of male astronauts inside a spacecraft (5.0 g cm-2) after the August 1972 SPE (Hu 
et al. 2009). 
 
 
B. Hematopoietic Response Models 
   
The radiation-induced perturbation of the hematopoietic system has been intensively 
investigated for several decades (Bond et al. 1965), and attempts have been made to model this 
complex system via biomathematical methods (Steinbach et al. 1980; Wichmann and Loeffler 
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1985; Fliedner et al. 1996). However, these models are built upon a very detailed architectural 
organization from hematopoietic stem cells (HSCs) to mature blood cells, which are speculated to 
comprise up to 31 stages (Dingli et al. 2007)  and contain a large number of variables and 
coefficients that are difficult to determine experimentally. A set of coarse-grained hematopoiesis 
models introduced by Smirnova et al. (Zukhbaya and Smirnova 1991;Kovalev and Smirnova 1996) 
have been successfully utilized to simulate and interpret the experimental data derived from acute 
and chronic irradiation of rodents (Smirnova 1999; Smirnova and Yonezawa 2003, 2004). The 
models consider all four major cell lines (granulopoiesis, lymphopoiesis, erythropoiesis, and 
thrombopoiesis) in a framework of negative feedback control via an implicit regulation 
mechanism. Each cell line consists of either three or four coarse-grained compartments and explicit 
parameters measurable by conventional hematological and radiobiological methods (Kovalev and 
Smirnova 1996). Most models use several equations with explicit regulators to simplify the 
complicated chains of substances and reactions that are involved in the hematopoietic regulation 
(e.g., Fliedner et al. 1996; Wichmann and Loeffler 1985). It has been observed, however, that for 
each cell line, a network of hematopoietic cytokines exists that regulate cell viability, 
multiplication, and differentiation (Sachs 1996), and there are also nervous system factors 
characterized by myelinated and unmyelinated nerve fibers in bone marrow that control cellular 
flow. In addition, there are cellular factors such as the continuous migration of HSCs through the 
blood that assure a sufficient number of HSCs in each bone marrow subunit (Fliedner et al. 2002). 
These factors work together to allow the heterogeneously distributed bone marrow to act and react 
as “one organ” in the complicated cell renewal processes throughout the entire body. An implicit 
treatment of such a complex mechanism is superior to the explicit treatment, as the regulation 
events are not just local but more similar to how a system operates across all levels of organization. 
With this advantage and the simplified coarse-grained hematopoietic compartmental structure, 
effects of various radiation conditions can be easily incorporated into the cellular kinetic equations, 
and a dynamic relationship between the peripheral blood cells and the bone marrow precursor cells 
after radiation damage can be rigorously established (Kovalev and Smirnova 1996; Hu and 
Cucinotta 2011).  
The granulopoietic model proposed by Smirnova et al. (2011) has been extended from 
rodents to large animals and humans (Hu and Cucinotta 2011a). By introducing species-dependent 
hematopoietic and radiobiological parameters, the granulopoietic model can generate results 
consistent with the data from experiments on beagle dogs and rhesus monkeys, as well as with 
acute, protracted, and chronic radiation conditions from various sources (Hu and Cucinotta 2011b). 
This implies that this model may provide a correct quantitative description of the hematopoietic 
response that covers a broad range of radiation conditions and species and could be a potential 
unified model with which to characterize mammalian hematopoietic responses after irradiation. 
By extending the model to humans, some empirical data on the hematopoietic response of victims 
after radiation accidents can also be reconstructed. In addition, this model can calculate the survival 
portion of bone marrow precursor cells after various types of exposure, which is essential for 
determining the likelihood of reversible or irreversible injury of the hematopoietic system 
(Fliedner et al. 1996). As an application in space radiation risk assessment, the model can be used 
to simulate the possible suppression of granulocytes in an astronaut in interplanetary space under 
chronic stress from low-dose irradiation, as well as the granulopoietic response if a historically 
large SPE is encountered (Hu and Cucinotta 2011b). 
For long-duration space missions beyond low-Earth orbit, crew members will be exposed 
to a chronic background of high-LET GCR with the possibility of encountering a large but 
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infrequent SPE. Figure 5a shows the modeled granulopoietic effects under the chronic dose rate 
of 1.5 mSv/d, which has been predicted for the GCR dose near a solar minimum (Cucinotta et al. 
2006). Though the level of granulocytes in blood is just slightly depressed, according to this model, 
there will be a persistent presence of weakly damaged X1 cells in bone marrow. Figure 5b shows 
the simulated granulocyte modulation for an astronaut in a typical spacecraft traveling in 
interplanetary space if he encounters a SPE 100 days after the launch. The SPE is postulated to be 
the same as the historically worst-case August 2, 1972, event. At the peak of this event, the 
exposure in a lightly shielded spacecraft (5.0 g/cm2) would have been about 443.0 mSv over a 10-
hour increment (Hu et al. 2009), assuming that crew members do not seek shelter in a more heavily 
shielded storm shelter. In this example, the chronic GCR dose rates are assumed to be 1.0 mSv/d 
to more closely represent solar maximum conditions, as large SPEs are known to occur at different 
parts of the solar cycle. The granulocyte concentration in blood can be as low as 75% of the normal 
level shortly after the peak of an SPE. At the nadir of the granulocyte counts, the level of intact X1 
cells in bone marrow is about 35% of the normal level because most cells in this pool experience 
at least weak damage from the high-dose-rate irradiation. Previous studies indicate that such an 
adverse scenario within a short period will not cause hematopoietic failure and that the system will 
recover automatically (Fliedner et al. 1996; Wilson et al. 1997). However, the response of the 
system to additional SPEs would be weakened, a situation that is possible during long-duration 
space missions (Kim et al. 2009a). This scenario is the basis for the 1970 National Academy of 
Sciences (NAS/NRC 1970) recommendation for a 0.50 Sv/y limit for the protection of the blood 
system that is still currently used by NASA.  
 
 
 
 
Figure 5. Granulocyte levels after space radiation exposures (Hu and Cucinotta 2011b). (a) Reduction of 
granulocytes under 1.5 mSv/d of continuous exposure to GCR at solar minimum. The concentrations of 
intact and weakly damaged X1 cells in bone marrow are also shown. (b) Modulation of granulocyte levels 
and intact precursor cells if an astronaut encounters the historically worst SPE. Before and after the SPE, 
the dose rate of GCR is assumed to be 1.0 mSv/d.  
 
 
  A recent investigation indicated that the lymphopoiesis model proposed by Smirnova can 
also qualitatively and quantitatively describe a wide range of accidental data in vastly different 
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scenarios if adapted with model parameters for humans (Hu et al. 2012). The results are consistent 
with the two widely recognized empirical biodosimetric tools, Guskova’s method and Goans’ 
method, demonstrating the potential to use the models as an alternative method for the assessment 
of radiation injury. In accidental situations, the exposure may involve poorly penetrating beta 
radiation and very penetrating gamma-ray, X-ray, thermal, and intermediate neutron radiation 
(Guskova et al. 2001). Thus, most individuals involved in accidents received non-uniform 
irradiation rather than uniform whole-body irradiation. Biodosimetric markers, such as persistent 
lymphopenia or the cytogenetic assay, are particularly important for assessing whole-body 
damage, as they reflect the average response required to cope with the injuries at various levels of 
the physiological system (Guskova et al. 2001). They also provide more accurate information for 
medical decision-making than physical detection devices (Dainiak 2002). The lymphopoiesis 
model is therefore very useful for interpreting biodosimetric marker data following accidental 
radiation exposures (Hu et al. 2012).  
  Thrombopoietic and erythropoietic models have also been extended to describe human 
hematopoietic responses after acute radiation or during chronic radiation exposures (Smirnova 
2012). In essence, all hematopoietic cell renewal systems have a very similar structure and function 
(Fliedner et al. 2002). The hematopoiesis models proposed by Smirnova et al. (2009) describe the 
mechanism of blood cell production starting from the pluripotent stem cell through different 
development stages, represented by the coarse-grained compartments, and the degree of cellular 
loss quantified by the radiosensitivity parameters of each compartment as well as the absorbed 
doses. The underlying implicit regulation mechanisms reflect the features of a systems-level 
response of the hematopoietic system to exogenous perturbations, which is reflective of the fact 
that the bone marrow, though heterogeneously distributed throughout the skeleton, acts as one 
organ of blood cell renewal for the whole body. Such a scheme seems to be applicable to all 
hematopoietic cell lineages and different radiation conditions (Hu et al. 2012; Hu and Cucinotta 
2013); thus, it is possible to develop a unified model to characterize mammalian hematopoietic 
responses after irradiation, which has been pursued by many researchers for several decades (Bond 
et al. 1965; Fliedner et al. 2007). 
 
C. Epidermal Response Models 
 
It is interesting that such a scheme can also be applied to simulate the cellular alterations 
observed in the patches of skin epidermis exposed to high-dose acute irradiation (Smirnova et al. 
2014). In this model, the epidermal keratinocytes are separated into three groups according to the 
degree of their maturity and differentiation:  
 X: the dividing maturing cells of the basal layer (from stem cells to mature basal cells); 
 Y: the maturing cells of the joint spinous/granular layer (from spinous cells to granular 
cells, i.e., prickle cells); 
 Z: the cells of the corneal layer (corneal cells or squames). 
The dynamics of the skin epidermal epithelium are represented by a system of ordinary differential 
equations, which resemble those used in the models of major hematopoietic lineages discussed 
above. With cell kinetics parameters experimentally determined in swine epidermis, the modeling 
results for the dose- and time-dependent changes in basal and prickle cell populations are in good 
agreement with relevant experimental data. In addition, the simulations also reveal that a 
correlation exists between the dynamics of a moist reaction experimentally observed and the 
corresponding in silico dynamics of corneal cells. From this information, the threshold level of 
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corneal cells (which indicates the appearance of the moist reaction) can be identified (Smirnova et 
al. 2014). 
A different approach using a multiscale soft tissue framework can also be employed to 
simulate the skin epidermal homeostasis and radiation responses (Hu and Cucinotta 2014). The 
model couples the following fundamental processes: 
 Subcellular level: Wnt signaling, cell-cell adhesion, and cell-cycle control; 
 Cellular level: Cell division, migration, and differentiation; 
 Macroscale level: Extracellular Wnt profile, cell-cell adhesion, and basal cell-BM 
adhesion. 
The connections between cells are modeled as springs, and Voronoi tessellation is used to associate 
the cell centers and to determine the size and shape of every cell in the aggregate. The cell-cycle 
progression, cell-cell adhesion, and differentiation states are influenced by intra-, inter-, and 
extracellular cues. By incorporating experimentally measured histological and cell kinetic 
parameters in this well-developed multiscale tissue framework, population kinetics and 
proliferation index results comparable to observations in unirradiated and acutely irradiated swine 
experiments can be obtained (Hu and Cucinotta 2014). Based on the simulation results, it can be 
demonstrated that a moderate increase in the proliferation rate of the surviving proliferative cells 
is sufficient to fully repopulate the area denuded by high doses of radiation, as long as the integrity 
of the underlying basement membrane is maintained. The importance of considering proliferation 
kinetics as well as the spatial organization of tissues during in vivo investigations of radiation 
responses is also highlighted.  
The epidermis of swine is known as the closest to that of humans in terms of structure, 
histology, and cell kinetics. Nevertheless, extrapolation of the developed models to humans needs 
further investigation, as some subtle differences between the epidermis of swine and human are 
known even from early studies (Montagna and Yun 1964).  
 
VI. Risk in Context of Exploration Mission Operational Scenarios 
 
A. Cumulative Probability of a Solar Particle Event Occurrence during a Given Mission 
Period 
 
Estimates of likely SPE cumulative doses and dose rates at critical organs are important for 
assessing the probability of ARS for specific mission scenarios. Detailed spectra and temporal 
information are available for most of the SPEs that have occurred since 1955. An analysis of nitrate 
concentrations in Arctic ice core samples provided data on integral fluences that are above 30 MeV 
for SPEs dating back to the 15th century (McKracken et al. 2001). However, recent work by 
Schrijver et al. (2012) has shown that the statistics of nitrates cannot be used as a proxy for the 
statistics of SPEs. Therefore, ice core data should not be used either for frequency analysis or to 
set upper limits of events. The use of nitrates as a proxy for SPEs should be removed from current 
analysis tools and not used in future work. Other proxies, such as lunar and terrestrial 
radionuclides, may be of use in constraining the upper limit of SPE fluences (Schrijver et al. 2012). 
Recent work by Kovaltsov and Usoskin (2014) revealed that an SPE with energy > 30 MeV and 
proton fluence > 1011 (protons/cm2 per year) is not expected on mega-year timescales based on 
lunar radionuclide data.  
For recent solar cycles 19 through 21 (1955–1986), a list of major SPEs and associated 
proton fluences has been assembled by Shea and Smart (1990), who placed all of the available flux 
 28 
and fluence data in a useful continuous database. From 1986 to the present (solar cycles 22 and 
24), both an SPE list and the Geostationary Operational Environmental Satellite (GOES) spacecraft 
measurements of the 5-minute-average integral proton flux can be obtained through direct access 
to the National Oceanographic and Atmospheric Agency (NOAA) National Geophysical Data 
Center. Work was done by Xapsos et al. (2004) to utilize data from the Goddard Medium Energy 
(GME) instrument on board the Interplanetary Monitory Platform 8 (IMP-8) satellite along with 
the GOES series in a consistent manner. The GOES data were calibrated to the IMP-8 data and re-
binned to the finer energy bins of the GME instrument. This provides a consistent dataset from 
1973 through 2006. The SPEs identified during solar cycles 19–23 varied significantly in the 
overall distribution of Φ30 from cycle to cycle.  However, fluence data of Φ30 were combined over 
all 5 cycles to estimate an overall probability distribution of an average cycle.   
While the expected frequency of SPEs is strongly influenced by the phase of the solar 
activity cycle, the SPE occurrences themselves are random in nature. The onset dates of a total of 
370 SPEs during solar cycles 19–23 are marked in the top of Figure 6 as brown vertical lines.  
More frequent SPE occurrences are shown as dense vertical lines, which are located typically near 
the middle of cycles. Large SPEs with proton fluences at energies > 30 MeV, F30 > 1107 
protons/cm2 are also shown. Other than a general increase in SPE occurrence with increased solar 
activity, recent solar cycles have yielded no recognizable pattern of when and how large individual 
SPEs occur (Goswami et al. 1988; Kim et al. 2005, 2009b, 2011). There have been several 
occurrences of intense SPEs during solar active years, which are typically 2.5 years before and 4.5 
years after solar maximum. The data in Figure 6 lead to the observation that individual SPE size 
is randomly distributed. This sporadic behavior of SPE occurrence and event size is a major 
operational problem in planning for missions to the moon and Mars. 
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Figure 6. SPE onset date marked as vertical lines in the top of the figure, and large SPEs recorded during 
5 modern solar cycles with integral proton fluences of F30, F60, and F100 > 1107 protons/cm2 with energies 
> 30, > 60, and > 100 MeV, respectively (Kim et al. 2011). 
 
To address the random nature of SPE occurrences and event sizes, a probabilistic approach 
to modeling has been the method that is often used, starting with the work of King (1974). In 
addition, the NASA JPL proton fluence model (Feynman 2002), the Moscow State University 
probabilistic SPE model (Nymmik 1999), and the Emission of Solar Proton (ESP) model (Xapsos 
1999, 2000, 2007) have used similar methods to those of King. The ESA SEPEM model (Jiggens 
2012) uses a virtual timeline methodology. All of these efforts utilize historical measurements, as 
available, and provide a cumulative SPE spectrum at some confidence level. This work is useful 
for mission design, as a range of confidence levels can be considered during the design phase. The 
work of Kim et al. (2009a) incorporates the probabilistic modeling framework but builds the 
probabilities from historical mathematical models of large SPE spectra. 
 
B. Spectral Representation of Solar Particle Events 
 
The shapes of the energy spectra, as well as the total fluence, vary considerably from event 
to event. Accurate organ dose estimates and particle spectra models are needed to ensure astronauts 
stay below radiation limits and to support the goal of narrowing the uncertainties in risk projections 
(Cucinotta et al. 2010). For the radiation dose assessments of astronauts from SPEs, spectral forms 
of incident particles extending to a few GeV have been fitted with available measurements up to 
~100 MeV. Those functional forms, an exponential in rigidity (Schaefer 1957;Freier and Webber, 
1963;King 1974) and a nonlinear regression of Weibull (Xapsos et al. 2000;Kim et al. 2009b), are 
simple and useful representations of the spectrum of SPEs; however, the spectral assumption 
1.E+07
1.E+08
1.E+09
1.E+10
2/
1/
19
54
2/
1/
19
56
2/
1/
19
58
2/
1/
19
60
2/
1/
19
62
2/
1/
19
64
2/
1/
19
66
2/
1/
19
68
2/
1/
19
70
2/
1/
19
72
2/
1/
19
74
2/
1/
19
76
2/
1/
19
78
2/
1/
19
80
2/
1/
19
82
2/
1/
19
84
2/
1/
19
86
2/
1/
19
88
2/
1/
19
90
2/
1/
19
92
2/
1/
19
94
2/
1/
19
96
2/
1/
19
98
2/
1/
20
00
2/
1/
20
02
2/
1/
20
04
2/
1/
20
06
Date
F
6
0
, 
p
ro
to
n
s
 c
m
-2
1.E+07
1.E+08
1.E+09
1.E+10
2/
1/
19
54
2/
1/
19
57
2/
1/
19
60
2/
1/
19
63
2/
1/
19
66
2/
1/
19
69
2/
1/
19
72
2/
1/
19
75
2/
1/
19
78
2/
1/
19
81
2/
1/
19
84
2/
1/
19
87
2/
1/
19
90
2/
1/
19
93
2/
1/
19
96
2/
1/
19
99
2/
1/
20
02
2/
1/
20
05
Date
F
1
0
0
, 
p
ro
to
n
s
 c
m
-2
1.E+07
1.E+08
1.E+09
1.E+10
1.E+11
2/
1/
19
54
2/
1/
19
57
2/
1/
19
60
2/
1/
19
63
2/
1/
19
66
2/
1/
19
69
2/
1/
19
72
2/
1/
19
75
2/
1/
19
78
2/
1/
19
81
2/
1/
19
84
2/
1/
19
87
2/
1/
19
90
2/
1/
19
93
2/
1/
19
96
2/
1/
19
99
2/
1/
20
02
2/
1/
20
05
Date
F
3
0
, 
p
ro
to
n
s
 c
m
-2
SPE onset date
19 20 2                   22 23
 30 
beyond ~500 MeV may result in the systematic uncertainty in radiation dose assessments of 
astronauts. With currently available assets, the energy spectrum of SPEs is only accurate up to 
approximately 500 MeV. Further constraint of the high-energy tail of the spectrum requires 
additional information not previously available from space assets. PAMELA (Adriani et al. 2015) 
provides direct measurements of the high-energy tail, but the measurements are limited due to its 
location in LEO.  Ground-based neutron monitors, however, can also help provide constraints for 
the high-energy tail of the SPE spectrum. 
A simplified technique for analyzing data from the world-wide neutron monitor (NM) 
network has been developed by Tylka and Dietrich (2009). They derived absolutely-normalized 
event-integrated proton spectra from the ground-level enhanced (GLE) event database. In this 
method, the fluences were extracted for individual NM stations with the quantification of the 
internal consistency of the results. The combined satellite and NM data from ~10 MeV to ~10 GeV 
from major SPEs (Tylka and Dietrich 2009) were presented as a double power law in rigidity, a 
so-called Band function (Band et al., 1993): 
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where R in GV, E in MeV, and 1 and 2 are the spectral indexes.  
 
Several large SPEs with GLEs recorded by neutron monitors are the events on 23 February 
1956, 12-15 November 1960, 29 September 1989, 4-7 August 1972, and 19-24 October 1989. 
Their event-integrated differential spectra have been compared for three different functional forms 
using different spectral representations of large SPEs. Variations of exposure levels were 
compared as an approach to the development of improved radiation protection for astronauts, as 
well as the optimization of mission planning and shielding for future space missions.   
  The question of how to handle the extrapolation of SPEs at Earth to Mars and beyond is 
ongoing. Specifically, the radial dependence of SPEs and how to extrapolate particle fluences 
beyond 1 astronomical unit (AU) (1 AU ≈ 1.5x108 km) were investigated by Smart and Shea 
(2003). Smart and Shea found that the radial dependence of the SPE flux had a range from R-2 (for 
R< 1 AU) to R-4 (for R > 1 AU), where R is the radial heliospheric distance. Recent modeling work 
(Aran et al. 2005; Kozarev et al. 2010; Verkhoglyadova et al. 2012) and observations (Lario et al. 
2006) revealed that the power law index values can vary significantly from the findings of Smart 
and Shea (2003). Some variables identified as affecting the variation in the power index include 
the particle energy range studied and coronal mass ejection shock obliquity and shock speed (Aran 
et al. 2005; Kozarev et al. 2010; Verkhoglyadova et al. 2012).     
 
 
C. Temporal Profiles of Solar Particle Events 
 
During a large SPE, there is a sudden increase in proton flux, especially for particles with 
energies greater than 50 MeV. The time profile of an individual SPE can be very complex due to 
the complicated acceleration mechanisms driving the SPE. Some SPEs can exhibit a sharp onset 
of high-energy protons after the major pulse (Reames 1999).  While the fluence during this 
secondary onset may not be as large as that during the peak, the sudden increase in dose rate is an 
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open question with important implications for acute responses to SPEs due to the dose-rate 
dependence (NCRP 2000). 
  Total fluence of an SPE is the representative indicator of a large SPE. The detailed energy 
spectra for a large SPE, especially at high energies, is the most important parameter for assessing 
the risk of radiation exposure (Kim et al. 2006; Schwadron et al. 2010), and dose rate-dependent 
factors are important for assessing biological acute responses (NCRP 2000).  A detailed temporal 
analysis of dose rate at the BFO for each SPE shows the highest dose rate at its peak, at which 
point significant biological damage would occur in a crew if adequate shielding is not provided 
(Hu et al. 2009). Early biological effects are expected to increase significantly for dose rates above 
0.05 Gy/h. For an extended EVA, the current recommended 30-day exposure limit for the BFOs, 
which is 0.25 Gy-Eq (NCRP 2000), is easily exceeded without sufficient shelter. 
   A simplified model of SPE temporal variation that includes an exponential rise to a peak 
intensity followed by a slow decay to background levels is often used as input to obtain dose and 
dose rate information of interest for modeling acute radiation risk (ARR). According to the 
temporal evolution of Φ30 with the assumption of the same spectral shape of each SPE at each time 
step, the dose rate distribution is estimated from the total SPE exposure. The early radiation risks 
are assessed from the BFO dose and dose rate by using the probabilistic biomathematical models 
of ARR (Anno et al. 1996; Hu et al. 2009;Hu and Cucinotta 2011;Hu et al. 2012), which include 
lymphocyte depression, granulocyte modulation, fatigue and weakness syndrome, and upper 
gastrointestinal distress. The temporal profiles of severities of the relevant symptoms are 
simulated, and the incidence rate of individuals is estimated at the 95% confidence interval.  
 
D. Shielding Material and Shielding Distribution of Spacecraft 
 
The early effects from acute exposure may not be avoided when only a conventional 
amount of spacecraft material is provided to protect the BFO from a large SPE. To avoid placing 
unrealistic mass on a space vehicle while at the same time increasing safety levels for the 
astronauts, one solution for shielding against SPEs is to select optimal materials for the vehicle 
structure and shielding. To this end, it has been shown that materials that have lower atomic mass 
constituents have better shielding effectiveness (Wilson et al. 1999; Cucinotta 1999). Overall 
exposure levels from large SPEs that have been recorded in the modern era can be reduced to 
below 0.1 Sv when heavily shielded “storm shelters” are added to a typical spacecraft (Kim et al. 
2006). Interpretation of this result, however, should be made while keeping in mind the caveat that 
significant uncertainties are inherent in determining the source spectra of protons (Musgrave et al. 
2009). 
  In the development of an integrated strategy to provide astronauts maximal radiation 
protection with consideration of the mass constraints of space missions, the detailed variation of 
radiation shielding properties (Kim et al. 2010;Walker et al. 2013) is considered to improve 
exposure risk estimations. For shielding analysis at a specific location in the spacecraft, shielding 
distributions can be evaluated. Currently, ARS due to SPEs can be assessed using the ARRBOD 
(Kim et al. 2010) and OLTARIS (Singleterry et al. 2010) models, which incorporate the shielding 
distributions of various spacecraft, including the conceptual lunar/Mars/NEA transfer capsule, 
lunar habitat, command module of Apollo, various locations within MIR (Badhwar et al. 2002), 
locations of the six passive radiation dosimeters of Shuttle (Atwell et al. 1987), and the six 
radiation area monitors of the International Space Station (Wilson et al. 2006).  OLTARIS allows 
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users to upload their own thickness distributions utilizing user-defined material properties for 
assessment and optimization.  
  In addition, optimization of storm shelters has been considered. Walker et al. (2013) and 
Simon et al. (2013) recently analyzed a trade space of different shield design concepts, including 
storm shelter placement within the vehicle, for multiple historic SPE spectra. The metric for 
shielding effectiveness in these studies was the reduction in effective radiation dose relative to the 
dose derived from nominal shielding conditions. 
 
E. Solar Alert and Monitoring 
 
An effective operational procedure requires an SPE warning or alert system. This system, 
which would be activated at the onset of proton exposure, would include pertinent information 
concerning the event, such as the fluence or flux and the energy distribution. These capabilities do 
not currently exist, and forecasts from NOAA are limited. New capabilities for deep space mission 
forecasting will be needed prior to a Mars mission because the alignment of the Earth and Mars 
does not allow all SPEs on Mars to be observed from Earth. A  report by the NRC discussed 
research approaches in space science that should lead to improved forecasting and alert capabilities 
for SPEs (NAS/NRC 2006), including a status of approaches supported by the NASA Science 
Mission Directorate. 
The most likely outcome of an SPE is mission disruption, with little or no harm to the crew, 
because despite the occurrence of some very large SPEs (e.g., the 1972 event described previously), 
more than 90% of SPEs result in very small radiation doses to critical organs (<100 mGy-Eq) (Kim 
et al. 2011). The other 10% of events can yield biologically significant doses and dose rates and 
are a concern for astronaut health and, therefore, mission planning. 
Still, mission disruption is possible because the size of the SPE cannot be determined until 
several hours after its initial onset. Reliable radiation dosimeters that can transmit information to 
mission control and provide a self-alert to astronauts are required. Such instrumentation has been 
available for many years, including during the Apollo missions (NCRP 1989a). In 2009, a 
workshop was held to determine operational requirements for forecasting as well as the state of 
forecasting capability (Fry et al. 2010). The workshop concluded that models were sufficiently 
mature to begin assessing them against operational requirements and that there would be benefit 
from future research. Since the workshop, further research has been performed to improve dose 
forecasting using regression techniques (Moussa and Townsend 2014). Additionally, a statistical 
method to evaluate forecasting performance using five different metrics was developed and 
applied to four different forecasting models (Falconer et al. 2014).  
  
F. Acute Radiation Risk and BRYNTRN (Baryon Transport) Organ Dose Projection 
(ARRBOD)  
 
  The Acute Radiation Risk and BRYNTRN Organ Dose (ARRBOD) projection code has 
been developed as a NASA tool to evaluate acute risks and organ doses from SPE exposures. 
ARRBOD (Kim et al. 2010), which includes the baryon transport code of BRYNTRN (Cucinotta 
et al. 1994;Wilson et al. 1989) and an output data processing code of SUMDOSE, is used to 
estimate the whole-body effective dose for astronauts. The radiation shielding by body tissue at 
specific organ sites is accounted for by using ray tracing in the human phantom models of the 
Computerized Anatomical Male (CAM) model (Kase et al. 1970; Billings and Yucker 1973) and 
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the Computerized Anatomical Female (CAF) model (Yucker and Hudston 1990; Yucker 1992). 
By implementing the NCRP’s recommended RBE (NCRP 2000) and the full definition of neutron 
RBE suggested by Wilson et al. (2002), the dosimetric quantities of various organs in gray-
equivalents (Gy-Eq) are calculated for male and female astronauts in case they encounter 
historically intense SPEs during transition and on the surface during lunar or Mars missions. The 
resultant organ doses for skin, eye, and BFO are compared with the current 30-day PELs (Table 
1). The severity of possible ARS is assessed from the BFO dose by using the NASA-developed 
probabilistic model ARRBOD (Anno et al. 1996; Hu et al. 2009).  
  For SPE environments, ARRBOD uses the exponential spectrum and Weibull distribution 
function. These two functional forms can fit available satellite measurements up to ~100 MeV. 
The recent analysis of the SPE spectrum of the Band function is included, which fits the combined 
satellite and neutron monitor data to improve the spectral fits from ~10 MeV to ~10 GeV (Tylka 
and Dietrich 2009). In addition, as the overall probability distribution of SPE fluence for an 
average cycle is estimated from the proton fluence data with energy greater than 30 MeV (F30) for 
cycles 19-23 (Kim et al. 2009a), a probability level of proton fluence can be specified by the user 
to analyze the exposure from SPEs. This is because the overall distribution of F30 is statistically 
significantly different from cycle to cycle in the recorded SPE data. To simulate the protracted 
effects of radiation exposure from SPEs, a simple representative temporal profile of SPE is 
modeled for the particle flux evolution by using a pulse function, which is parameterized by two 
time constants (the rise and decay times) and the ratio of proton flux for energies greater than 30 
MeV at the peak to the onset. 
With the temporal profile of the SPE described, both the temporal profile of the BFO dose 
rate within the spacecraft and the temporal profile of the EVA BFO dose rate can be generated for 
male and female astronauts. Once IVA and EVA timelines are established, the acute health 
response information of lymphocyte depression, granulocyte modulation, fatigue and weakness 
syndrome, and upper gastrointestinal distress is generated by NASA-developed prodromal risk 
models and hematopoietic models (Hu et al. 2009;Hu and Cucinotta 2011a, 2011b;Hu et al. 2012). 
 
G. Potential for Biological Countermeasures 
 
Radiation countermeasures can include radioprotectors, mitigators, and treatments.  
Radioprotectors, such as antioxidants, are agents that are given prior to exposure to reduce the 
damage to various organs by radiation (Gudkow and Komarova 2005), while mitigators are agents 
given during or shortly after exposure (Stone et al. 2004; Bourgier et al. 2012). Biological 
countermeasures under development for use in clinical practice and against radiological threats are 
expected to provide risk reduction for low-LET radiation delivered at high doses and dose rates. 
However, their effectiveness at low dose rates and for high-LET solar particle radiation is less 
clear and may be distinct from the countermeasures required for the other space radiation risks of 
cancer, central nervous system, and degenerative tissue effects. The likelihood that an SPE will 
produce doses that are above 1 Gy is small, but the occurrence of doses that can induce prodromal 
risks is possible. Although the prodromal syndrome, including nausea, vomiting, anorexia, and 
diarrhea, may seem more innocuous than the other symptoms of ARS, biological countermeasures 
for the prodromal risks are a major consideration. Ondansetron (Zofran®), a 5-HT3 serotonin 
antagonist, is a biological countermeasure that has been tested in animal models under space-
relevant doses and dose rates (King et al. 1999) and is approved clinically for the treatment of 
nausea associated with radiotherapy. Ondansetron has demonstrated effectiveness in reducing 
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emetic risk due to space-relevant ionizing radiation and is currently used on the ISS for nausea and 
vomiting (Kennedy 2014).  Oral anti-diarrheal agents are included in the ISS medical kit to 
ameliorate symptoms associated with diarrhea.  While the risk of infection is another factor that 
requires attention, current medical kits include a range of antibiotics, namely, penicillins, 
cephalosporins, and macrolides (Marshburn 2008), that will be available to support a weakened 
immune system. These treatments have been successfully delivered orally or via intramuscular 
injection on previous space missions.   
Following the prodromal phase, there is concern for the occurrence of hematopoietic 
syndrome at the anticipated exposure doses given the potential for the bone marrow to be 
compromised at doses as low as 0.5 Gy (Mettler 2012). There are several mechanisms being 
targeted for the development of radiation countermeasures to address hematopoietic syndrome, 
including the scavenging of free radicals, blocking cell death signals, facilitating repair of damaged 
molecules, and inducing regeneration of injured tissue (Whitnall 2012).  A summary of several 
radioprotectors and mitigators that have been explored to treat hematopoietic syndrome and their 
various stages of development are outlined in Table 6. One of the more successful radiation 
mitigators, filgrastim (Neupogen®, Amgen), is a granulocyte colony stimulating factor that has 
shown promise in several studies when administered post-exposure and is currently part of the US 
National Strategic Stockpile (Xiao and Whitnall 2009; Farese et al. 2013). Neupogen® received 
FDA approval in 2015 for the additional indication to “increase survival in patients acutely 
exposed to myelosuppressive doses of radiation” (FDA 2015). The recommended dosage for 
patients acutely exposed to myelosuppressive doses of radiation is 10 mcg/kg/day by subcutaneous 
injection (Amgen 2015).  The sustained release version, pegfilgastrim (Neulasta®), reduced 
neutropenia in studies involving SPE-like protons (Romero-Weaver et al. 2013) and has recently 
received FDA approval (FDA 2015) for the same indication as Neupogen® with a recommended 
dosage of 0.1mg/kg subcutaneously once per week for two weeks.  An automated subcutaneous 
delivery system was recently released by Amgen to facilitate delivery of Neupogen® and 
Neulasta®.  Antioxidants have also been investigated both in vitro and in vivo for their protective 
properties against radiation-induced oxidative stress, with several demonstrating promising results 
in SPE-relevant studies (Kennedy and Wan 2011;Kennedy 2014), and beta androstendediol 
administered post-irradiation had beneficial effects following heavy ion particle irradiation (Loria 
et al. 2011).  
The anticipated SPE exposure dose to the skin ranges from 0.5-5 Gy. At the higher doses, 
there is an increased likelihood of radiation dermatitis, which can result in irritation, pain, and skin 
infections that may ultimately compromise the immune system (Peebles et al. 2012; Ryan 2012). 
In studies involving minipigs exposed to 5 or 10 Gy of SPE-like protons, topical steroid cream 
(Elocon®) mitigated radiation-induced skin damage (Kennedy 2014). Radiation exposure to skin 
is currently treated as a burn. Medical kits provided on the ISS include silver sulfadiazine, sterile 
gauze, parenteral opioid analgesics, and crystalloid solutions (Marshburn 2008), although more 
advanced radioprotectors and mitigators may be required for longer duration missions. These may 
include targeted gene therapy with targets focused on the TGFβ1 pathway inhibitor, synthetic 
superoxide dismutase/catalase mimetics, recombinant IL-12, toll-like receptor-5 antagonist, and 
inhibitors of cyclin-dependent kinases (Ryan 2012).   
There are several biological radiation countermeasures currently available or under 
development that can be investigated to determine their efficacy in treating ARS due to SPEs. 
Several new therapies are also being explored, many of which are already in early-stage clinical 
trials, to evaluate their toxicity and safety as space radiation countermeasures. Mechanistic studies 
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of possible biochemical routes for countermeasure actions must be combined with approaches to 
extrapolate model system results to humans for such countermeasures to be used operationally by 
NASA. It will be important moving forward to bear in mind that the efficacy of any biological 
countermeasure will need to be determined under the appropriate dose and space radiation 
environment, and the impact on other risk areas must be considered. Selecting effective 
radioprotectors or mitigators will also involve practical concerns, such as ease of administration, 
effectiveness period, impact on performance, side effects, toxicity, shelf-life, and drug interactions, 
all of which will be factored into the adoption of any biological countermeasure. Continued 
surveillance of new technologies and radioprotectors/mitigators will guide the identification and 
validation of appropriate biological countermeasures for long-duration space missions. 
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Table 6. Summary of Biological Countermeasures Investigated for Radioprotection or Mitigation 
Radiation Countermeasures for Hematopoietic Syndrome 
Countermeasure Class Group Mechanism Testing Status References 
Neupogen Radiomitigator Recombinant growth 
factor 
Granulocyte Colony Stimulating 
Factor (G-CSF)  
Rhesus macaques  exposed to 7.5 Gy 
TBI gamma; delivery 1 and 8 days 
post-IR; increased  survival and 
neutrophil-related parameters 
FDA approval 
under Animal 
Rule 
Xiao 2009, Farese 
2013, 2014 
Neulasta (pegylated 
form of Neupgen) 
Radiomitigator Pegylated growth factor Granulocyte Colony Stimulating 
Factor (G-CSF)  
Rhesus macaques  exposed to 7.5 Gy 
TBI gamma; delivery 1 and 8 days 
post-IR; increased  survival and 
neutrophil-related parameters 
NHP studies 
conducted for 
FDA approval 
under Animal 
Rule 
Hankey 2015 
Sargramostim (Leukine) Radiomitigator Recombinant growth 
factor 
Granulocyte Colony Stimulating 
Factor (G-CSF)  
Rhesus macaques exposed to 7 Gy TBI 
60Co; delivery 1x/day for 23 days post-
IR; Recovery from severe neutropenia 
FDA approval for 
off-label use; 
included in SNS 
Gupta 2013 – FDA 
briefing package 
Amifostine (Ethyol) or 
WR-1065, WR-2721, 
WR-151,327 
 
Radioprotector Aminothiol Antioxidant; free radical scavenger; 
DNA protector 
B6CF1 exposed to 2 or 4 Gy TBI Co-60;  
B6CF1 exposed to 0.1 or 0.4 Gy TBI 
fission neutrons; delivery 30 min pre-
IR; increased survival; protected 
against specific tumors; protected 
against non-tumor complications; 
induces adaptive response 
FDA approval for 
renal toxicity and 
xerostemia in 
patients being 
treated for 
cancer 
Peebles 2012, Soref 
2011, Langell 2008, 
Xiao 2009, Paunesku 
2008, Grdina 2013, 
Bogo 1985 
PrC-210 Radioprotector aminothiol Antioxidant; free radical scavenger; 
DNA protector 
ICR mice exposed to 8.63-8.75 Gy TBI 
137Cs; delivery 30 min pre-IR; 
increased survival 
Testing ongoing 
at AFRRI 
Copp 2013 
B-190 (Indralin) Radioprotector alpha1-adrenergic 
receptor 
Vasoconstrictor; neutralizes the 
oxygen effect 
Rhesus macaques exposed to 6.8 Gy 
TBI 60Co; delivery 5 min pre-IR; 
antimicrobials post-IR: levomycetin 
1x/day for days 1-10 and pen/strep 
combination 1x/day for days 10-20; 
increased survival 
Testing ongoing 
in Russia 
Vasin 2014 
 37 
Androstenediol (5-AED) Radioprotector 
and mitigator 
Steroid Nuclear Factor-κβ; increases G-CSF 
and IL-6 
Rhesus macaques exposed to 4 Gy 
60Co TBI; delivery 3-4 hr post-IR; 
hematopoietic recovery 
FDA IND 
approval 
Grace 2012, Stickney 
2006, Whitnall 2005 
ON01210 (Ex-
RAD/Recilisib) 
 
Radioprotector 
and mitigator 
Chlorobenzylsulfone 
derivative 
Tyrosine kinase inhibitor; 
attenuation of ATM/p53 signaling; 
upregulation of PI3K signaling 
C3H/HeN mice exposed to 6 Gy TBI 
60Co; delivery 24 hr and 15 min pre-IR; 
mitigated neutropenia and bone 
marrow suppression; increased 
survival 
FDA IND 
approval 
Ghosh 2012, Singh 
2015, Kang 2013 
rhIL12 (HemaMax) Radiomitigator Recombinant cytokines Cytokine; inflammatory regulator; 
stimulates IFN-ɣ production, 
macrophages and T-cells 
Rhesus macaques  exposed to 7 Gy 
TBI Co-60; delivery 1 day post-IR; 
increased  survival  
FDA IND 
approval 
Basile 2012, 
Gluzman-Poltorak 
2014 
CBLB502 (Entolimid) Radioprotector 
and mitigator 
Flagellin derived protein Toll-like receptor 5 agonist; 
stimulates NF-κB signaling; 
stimulates G-CSF; free radical 
scavenger 
Rhesus macaques  exposed to 6.5 Gy 
TBI Co-60; delivery 45 min pre-IR; 
increased  survival 
FDA IND 
approval and 
orphan drug 
status 
Burdelya 2008, Singh 
2015, Rosen 2015 
PLacental eXpanded 
(PLX-R18) 
Radiomitigator Placental stromal cells 
with fetal offspring cells 
Immunomodulator; secretes 
cytokines, chemokines and growth 
factors 
C3H/HeN mice exposed to 7.7 Gy TBI  
6–18 MeV LINAC; delivery 24 hr and 5 
days post-IR; increased bone marrow 
hematopoietic cell proliferation 
Research 
ongoing; plans to 
pursue FDA 
animal rule 
approval 
Gaberman 2013 
CLT-008 Bridging therapy Myeloid progenitor cells Stimulates myeloid, erythroid and 
dendritic cell development; 
provides hematopoietic support 
CD2F1 mice exposed to 9 Gy TBI 60Co; 
delivery 2hr or 2 day or 4 days or 7 
days post-IR; increased survival 
In clinical trials 
for patients with 
hematological 
malignancies 
Singh 2012, 2015 
BIO 300 (Genestein) Radioprotector  Soy isoflavone, 
phytoestrogen 
Antioxidant; free radical scavenger; 
protein tyrosine kinase inhibitor; 
cell cycle modulator 
CD2F1 mice exposed to 9.25 Gy TBI 
60Co; delivery 24 hr pre-IR; increased 
survival; improved hematopoietic 
recovery 
FDA IND 
approval 
Ha 2013 
CDX-301 Radioprotector 
and mitigator 
Recombinant human 
protein form of the 
Fms-related tyrosine 
kinase 3 ligand (FLT3L), 
a hematopoietic 
cytokine 
stimulates expansion and 
differentiation of hematopoietic 
progenitor and stem cells 
C57BL/6 mice exposed to 7.76 TBI 
with 137Cs source; delivery 24 hr pre-
IR and 4 or 24 hr post-IR; increased 
survival 
NHP studies 
underway at 
AFRRI  
Thomas 2013 
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ALXN4100TPO Radioprotector 
and mitigator 
Thrombopoietin (TPO) 
receptor agonist 
Activates thrombopoietin 
receptor; stimulates platelet 
production 
CD2F1 mice exposed to 9 Gy TBI 60 Co; 
delivered 24hr pre-IR or 6 hr post-IR; 
abrogated thrombocytopenia and 
bone marrow atrophy   
Research 
ongoing 
Cary 2012, 
Satyamitra 2011 
WR-638 (Cystaphos) Radioprotector Aminoethylphosphor-
othioate 
Antioxidant; free radical scavenger; 
DNA protector 
Mice exposed to 7.5Gy TBI 60Co; 
delivered 30 min pre-IR; 
antimutagenic  
Carried in field 
pack by Russian 
army 
Hall, Method for 
protection against 
genotoxic 
mutagenesis  
Captopril and 
angiotensin converting 
enzyme (ACE) inhibitors 
Radiomitigator Anti-hypertensive drug Thiol mediated free radical 
scavenger 
C57BL/6 mice exposed to 6 or 7.5 Gy 
TBI 60Co; delivery pre-IR and varying 
regimen post-IR; delivery pre-IR 
conferred no protection; post-IR 
treatment increased survival and 
abrogated thrombocytopenia 
Research 
ongoing 
Davis 2010 
3,3’-Diindolylmethane 
(DIM) 
Radioprotector 
and mitigator 
Small molecule 
compound from the 
hydrolyzation of indole-
3-carbinol (I3C)  
Stimulates ATM signaling; DNA 
protector 
Sprague–Dawley (SD) rats and 
C57BL/6 mice exposed to 13 Gy TBI 
60Co; delivery post-IR 10min followed 
by 1x/day for 14 days; increased 
survival 
In clinical trials 
for other 
indications  
Fan 2013 
Oltipraz Radioprotector Synthetic ditholethione 
derived from broccoli 
Increased expression of 
microsomal epoxide hydrolase and 
glutathione S-transfer genes 
Mice exposed to 8 Gy TBI gamma; 
delivery pre-IR; increased survival 
In clinical trials 
for liver fat 
reduction and 
lung cancer 
prevention 
Singh 2014 
LY294002 or PX-867 
 
Radiomitigator Morpholine containing 
chemical compound 
Phosphoinisitide-3 kinase (PI3K) 
inhibitor 
C57BL/6NTac exposed to 9.25 Gy TBI 
with 137Cs; delivery 10 min, 4 h, 24 h, 
or 48 h post-IR; extends survival; 
abrogated cell death 
In clinical trial for 
neuroblastoma 
Zellefrow 2012, Lazo 
2013 
Minocycline Radioprotector 
and mitigator 
2nd generation 
tetracycline derivative 
Antibiotic; antioxidant; free radical 
scavenger  
C57BL/6 mice exposed to 1-3Gy TBI 
60Co; delivery 10min pre-IR then 10 
min post-IR and 1x/day for 3 days 
post-IR;  Modulates production of 
cytokines   
In clinical trials 
for 
neuroprotection 
during 
radiotherapy 
Mehrotra 2012, Kim 
2009, Tikka 2001 
FGF-peptide Radiomitigator Synthetic binding 
domain peptide of FGF-
2 with peptidase 
resistant dimer form 
Maintains stem cell pool; promotes 
differentiated cells 
NIH Swiss mice exposed to 6 Gy TBI 
with 137Cs; delivery 48hr post-IR 
1x/day for 5 days then 1x/day every 
other day for 10 days; increased the 
number of pro-B and pre-B cells 
Research 
ongoing 
Casey-Sawicki 2014 
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Fluoroquinolones Radioprotector 
and mitigator 
Broad-spectrum 
antibiotics that act 
against gram-positive 
and gram-negative 
bacteria 
Antibiotic; antioxidant; free radical 
scavenger  
C3Hf/Kam mice exposed to 8Gy TBI 
with 137Cs; delivery 24 hr or 1 hr pre-
IR or 24 hr post-IR then 5x/day; 
increased survival; enhanced 
hematopoiesis 
In clinical trials 
for antimicrobial 
indications 
Kim 2009, Shalit 1997 
Octadecenyl 
Thiophosphate (OTP) 
Radioprotector 
and mitigator 
Small Molecule Mimic 
of Lysophosphatidic 
Acid 
Receptor-mediated direct action; 
regulation of hematopoietic 
cytokine production 
C57BL/6 mice exposed to 6.3 Gy TBI 
137Cs; delivery 12 hr pre-IR or 24, 48 
and/or 72 hr post-IR; increased 
survival; enhanced hematopoiesis  
Research 
ongoing 
Deng 2015 
Dietary Supplements:  
Countermeasure Class Group Mechanism Testing Status References 
Ascorbic Acid (Vitamin 
C) 
Radioprotector 
and mitigator 
Dietary supplement Antioxidant; free radical scavenger C57BL/6 mice exposed to 7 to 8 Gy 
TBI X-ray; delivery immediately pre-IR 
or post IR or 1, 6, 12, 24, 36 or 48 hr 
post-IR; increased survival 
Regulated by 
FDA as a dietary 
supplement 
Sato 2015 
ɣ- Tocotrienol (GT3) 
 
Radioprotectant Small molecule; vitamin 
E isomer 
DNA protector; antioxidant; 
stimulates G-CSF 
CD2F1 mice exposed to 9.2 Gy TBI 
60Co; delivery 24 hr pre-IR; reduced 
DNA damage; reduced nitrosative 
stress; induced G-CSF 
NHP studies 
underway at 
AFRRI 
Kulkarni 2013, Singh 
2014 
δ – Tocotrienol (DT3) Radioprotectant Small molecule; vitamin 
E isomer 
DNA protector; antioxidant; 
immunomodulator 
CD2F1 mice exposed to 7–12.5 Gy TBI 
60Co; delivery 24 hr pre-IR; anti-
apoptosis; induces cytokines 
increased survival 
Research 
ongoing 
Li 2015, Singh 2014 
Mentha Piperita (Linn.) - 
peppermint 
Radioprotector  Herb antioxidant Swiss albino mice exposed to TBI of 
4,6,8 or 10Gy 60Co; delivery 3 days 
pre-IR; inhibited radiation induced 
GSH depletion; decreased LPO; 
increased phosphatase 
Herb; not 
regulated by FDA 
Samarth 2003 
Dragon’s Blood and 
extracts 
Radioprotector Resin from the fruit of 
Daemonorops draco 
tree 
anti-inflammatory; anti-apoptotic BALB/c mice exposed to 4Gy TBI 60Co; 
delivery 1x/day for 5 days pre-IR and 
1x/day for 1, 3, 7 or 28 days post-IR; 
mitigated oxidative stress in the liver 
and spleen; enhance immunity; 
hemostasis 
Herb; not 
regulated by FDA 
Ran 2014, Xin 2012 
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α-Lipoic acid  Radioprotector Organosulfur 
compound 
lipophilic antioxidant CD2F1 mice exposed to TBI of 9Gy 
60Co; delivery 30 min pre-IR; 
increased survival; dihydrolipoic acid 
had no radioprotective effect 
Regulated by 
FDA as a dietary 
supplement 
Ramakrishnan 1992 
Radiation Countermeasures for Gastrointestinal Syndrome 
Countermeasure Class               Group Mechanism Testing Status References 
ON01210 (Ex-
RAD/Recilisib) 
 
Radioprotector 
and mitigator 
Chlorobenzylsulfone 
derivative 
Tyrosine kinase inhibitor; 
attenuation of ATM/p53 signaling; 
upregulation of PI3K signaling 
C3H/HeN mice exposed to 13 and 14 
Gy TBI 60Co; delivery 24 hr and 15 min 
pre-IR; preserved intestinal crypt cells 
FDA IND 
approval 
Ghosh 2012, Singh 
2015, Kang 2013 
       
Cerium oxide 
nanoparticles 
Radioprotector Oxide of the rare earth 
metal Cerium 
Free radical scavenger; superoxide 
dismutase 2 regulator 
Athymic nude mice exposed to 20Gy; 
delivery 4x pre-IR; protected GI 
epithelium by ROS scavenging and 
increasing production of SOD2 
Research 
ongoing 
Colon 2009, 2010, 
Baker 2013 
TP508 (Chrysalin) Radiomitigator Rousalatide acetate 
regenerative peptide 
stimulates expression of adherens 
junction protein E-cadherin; 
activates crypt cell proliferation; 
decreases apoptosis 
Animals exposed to 9Gy TBI gamma 
radiation; delivery 24 post-IR; 
reduced GI toxicity; increased survival 
Pursuing FDA 
approval under 
Animal Rule 
Guidance 
Kantara 2015 
Pectin Radioprotector Dietary supplement; 
highly-complex 
branched 
polysaccharide fiber; 
rich in galactoside 
residues; present in all 
plant cell walls 
Inhibition of Notch signaling; anti-
inflammatory 
C57BL/6 mice exposed to 14 Gy TBI  
137Cs; delivery 1 week pre-IR and 
continued post-IR; prevents IR-
induced deletion of potential reserve 
ISCs; facilitated crypt regeneration; 
increased survival 
In clinical trials 
for intestinal 
support 
Sureban 2015 
OrbeShield/BDP 
 
Radiomitigator oral beclomethasone 
17,21-dipropionate; 
corticosterioid 
Induction of the Wnt-b-catenin 
pathway; Anti-inflammatory; 
vasoconstrictor 
Canines exposed to 12Gy TBI; delivery 
2 hr or 24 hr post-IR; increased 
survival; reduce epithelium damage 
FDA IND for GI 
ARS; FDA Orphan 
Drug Designation 
for ARS 
Soligenix 
Anti-ceramide antibody 
(2A2) 
Radioprotector Inflammatory molecule Transmits apoptotic signals; 
support recovery of crypt stem cell 
clonogens 
C57BL/6 mice exposed to 15Gy TBI 
137Cs; delivery 15 min pre-IR; inhibits 
radiation-induced endothelial 
apoptosis and crypt lethality; 
increased survival 
Research 
ongoing 
Rotolo 2012 
 41 
R-spondin1 (Rspo1) Radioprotector Protein Increase stem cell population; 
inhibit radiation induced apoptosis 
in crypt; stimulation of Wnt-b-
catenin signaling in RIGS 
C57Bl/6 mice exposed to 10.4Gy TBI 
137Cs; delivery of recombinant 
adenovirus expressing human R-
spondin1 using adenoviral gene 
transfer 1-3 days pre-IR; promoted 
intestinal stem cell regeneration; 
increased survival 
Research 
ongoing 
Bhanja 2009 
ON01210 (Ex-RAD) 
 
Radioprotector 
and mitigator 
Chlorobenzylsulfone 
derivative 
Tyrosine kinase inhibitor; 
attenuation of ATM/p53 signaling; 
upregulation of PI3K signaling 
C3H/HeN mice exposed to 13 and 14 
Gy TBI 60Co; delivery 24 hr and 15 min 
pre-IR; protected mucosal structure 
and crypt cells 
FDA IND 
approval 
Ghosh 2012, Singh 
2015 
δ – Tocotrienol (DT3) Radioprotector Small molecule; vitamin 
E isomer 
DNA protector; antioxidant; 
immunomodulator 
CD2F1 mice exposed to 10-12 Gy TBI 
60Co; delivery 24 hr pre-IR; protected 
intestinal tissue;  decreased 
apoptosis; inhibited gut bacterial 
translocation 
In clinical trials 
for support in 
radiation therapy 
Li 2013 
N-Acetyl Cysteine (NAC) Radioprotector 
and mitigator 
Amino acid Antioxidant C57BL/6 mice abdomen exposed to 
20 Gy X-ray Delivery 4hr pre-IR or 2hr 
post-IR and 1x/day for 6 days post-
IR;increased survival 
FDA approved to 
treat overdose of 
acetominophen 
Jia 2010 
α – tocopherol 
succinate (TS) 
Radioprotector Small molecule; vitamin 
E isomer 
DNA protector; antioxidant; 
immunomodulator 
CD2F1 mice exposed to 11 Gy TBI 
60Co; delivery 24 hr pre-IR; protected 
intestinal tissue;  improved structural 
integrity, inhibited apoptosis; 
enhanced cell 
In clinical trials 
for support in 
radiation therapy 
Singh 2013 
SOM230 (Pasireotide) Radioprotector 
and mitigator 
Somatostatin analog Preserves intestinal barrier 
function by decreased secretion of 
pancreatic enzymes 
CD2F1 mice exposed to 8.5-11Gy TBI 
137Cs; delivery 24-72hr post-IR twice 
daily for 14 days; suppression of 
secretion of pancreatic enzymes; 
increased survival 
Research 
ongoing with 
BARDA funding 
at UAMS 
Fu 2011, Singh 2015 
Octadecenyl 
Thiophosphate (OTP) 
Radioprotector 
and mitigator 
Small Molecule Mimic 
of Lysophosphatidic 
Acid 
Anti-apoptotic agent C57BL/6 mice exposed to 10.6 Gy TBI 
137Cs; delivery 2 hr pre-IR or 24hr 
post-IR; increased survival;restored 
glucose absorption and inhibited 
endotoxemia; significantly increased 
the number of regenerating crypts in 
the jejunum 
Research 
ongoing 
Deng 2015 
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Palifermin Radioprotector Recombinant N-
terminal truncated form 
of keratinocyte growth 
factor (KGF) 
Proliferation stimulation; anti-
apoptotic 
C57BL/6J mice exposed to 6 Gy TBI 
60Co; delivery 1x/day for 5 days pre-
IR;  improved distribution of tight 
junction proteins and epithelial 
barrier dysfunction 
Phase I/II/II/IV 
clinical trials for 
oral mucositis in 
patients with 
head and neck 
cancer; stem cell 
transplant 
immune 
recovery 
Singh 2014, Cai 2013 
Radiation Countermeasures for Skin 
Countermeasure Class               Group Mechanism Testing Status References 
PrC-210 Radioprotector aminothiol Antioxidant; free radical scavenger; 
DNA protector 
Rats backs exposed to 17.3 or 41.7Gy 
137Cs; 4 topical applications delivered 
2hr, 1hr, 30 min and 10 min pre-IR; 
98% prevention of radiation 
dermatitis 
Clinical trials for 
safety and 
efficacy for 
radiotherapy 
patients 
Peebles 2012 
FGF-peptide Radiomitigator Synthetic binding 
domain peptide of FGF-
2 with peptidase 
resistant dimer form 
Increases proliferation of 
keratinocytes; regulation of tight 
junction proteins 
BALB/C mice exposed to 50Gy 
strontium; delivered topically and 
systemically daily for 16 days; 
accelerated wound healing 
Research 
ongoing 
Zhang 2011 
Pravastatin Radiomitigator Statin Anti-oxidant; anti-inflammatory Balb/c mice exposed to 45 Gy TBI 
60Co; delivery in food daily post-IR for 
28 days; Modulated cytokines; limits 
downregulation of endothelial nitric 
oxide synthase 
FDA approved 
for treatment of 
high cholesterol 
Holler 2009 
Plerixafor Radiomitigator bicyclam compound  CXCR-4 antagonist;bone marrow 
stem cell mobilizer 
C57BL/6 mice exposed to 25-30 Gy X-
ray; delivery of 2 doses with 2 days 
between started either on day 0, 4, 7, 
15 or 24 post-IR; improves both acute 
and late skin response to radiation 
exposure 
FDA approval for 
immobilizing 
stem cells in 
non-hodgkin 
lymphoma and 
multiple 
myeloma 
Kim 2012 
Curcumin Radioprotector 
and mitigator 
Diarylheptanoid; phenol Anti-inflammatory; regulator of 
cytokines; antioxidant 
C3H/HeN mice exposed to 50Gy; 
delivery 5 days pre-IR or 5 days post-
IR or 5 days pre-IR and 5 days post-
IR; reduced acute and chronic skin 
toxicity 
In clinical trials 
for radiation 
dermatitis 
Okunieff 2006, Ryan 
2013 
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Radiation Countermeasures for Lung, Esophagus, Oral, Heart 
Countermeasure Class               Group Mechanism Testing Status References 
Manganese Superoxide 
Dismutase (MnSOD) 
Radimitigator Protein Anti-apoptotic; metabolizes 
reactive oxygen species 
9.5 Gy TBI; MnSOD combined with 
antioxidant diet extends life after ARS 
recovery 
In clinical trial for 
protection of 
radiation 
induced 
esophagitis 
Borelli 2009 
Rapamycin Radioprotector Small molecule MTOR inhibitor; blocks radiation 
induced cellular senescence 
C3H mice exposed to 30 Gy 
fractionation (6 Gy weekly); delivery 
1x/week; protects from the loss of 
proliferative basal epithelial stem 
cells; reduced DNA damage; did not 
confer protection when delivered 
with single dose of 15 Gy 
In clinical trials 
for head and 
neck cancer; 
NSCLC 
Iglesias-Bartolome 
2012, Rosen 2015 
Transforming growth 
Factor β3 (TGFβ3) 
Radiomitigator Protein Attenuates radiation induced 
pulmonary function 
Mice exposed to a single thoracic 
radiation of 20Gy; delivery weekly; 
decelerated progress of radiation 
induced fibrosis; slowed recruitment 
of fibrocytes; Th1 response 
suppressed 
Research 
ongoing 
Xu 2014, Rosen 2015 
AEOL 10150 Radioprotector 
and mitigator 
Metalloporphyrin Antioxidant; free radical scavenger Rhesus macaques exposed to 11.5 Gy 
of whole thorax lung irradiation; 
delivery 24 hr post-IR daily for 4 
weeks; reduced incidence of radiation 
induced lung injury 
FDA Orphan 
Drug Designation 
for ARS 
Garofalo 2014 
Palifermin (Kepivance) Radioprotector Recombinant N-
terminal truncated form 
of keratinocyte growth 
factor (KGF) 
Proliferation stimulation; anti-
apoptotic 
C57BL/6J mice exposed to 6 Gy TBI 
60Co; delivery 1x/day for 5 days pre-
IR;  recovery of mucosa 
Phase I/II/II/IV 
clinical trials for 
oral mucositis in 
patients with 
head and neck 
cancer; stem cell 
transplant 
immune 
recovery 
Singh 2014, Cai 2013 
Cerium oxide 
nanoparticles 
Radioprotector Oxide of the rare earth 
metal Cerium 
Free radical scavenger; superoxide 
dismutase 2 regulator 
Athymic nude mice exposed to 30Gy 
fractionation (5 Gy weekly); delivery 
2x/week; no visible pneumonitis 
Research 
ongoing 
Colon 2009, 2010, 
Baker 2013 
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Melatonin Radioprotector hormone Free radical scavenging; singlet 
oxygen quenching 
Wistar rats exposed to 18Gy 
2.5x2.5cm area of 60Co; delivery 15 
min pre-IR; vasculitis prevented; 
decreased fibrosis and myocyte 
necrosis; cardioprotective 
Wistar rats exposed to 18Gy 
2.5x2.5cm area of 60Co; delivery 15 
min pre-IR; lung injury reduced; 
fibrosis still present 
Regulated by 
FDA as a dietary 
supplement 
Gurses 2014, Serin 
2007, Tahamtan 
2015 
Radiation Countermeasures Tested in Space Radiation Simulated Environment 
Countermeasure Class               Group Mechanism Testing Status References 
Selenomethionine 
(SeM) 
Radioprotector Dietary antioxidant Maintains activities of the 
antioxidant enzymes glutathione 
peroxidase and thioredoxin 
reductase; regulate expression of 
genes involved in the repair of 
radiation-induced DNA damage 
Sprague-Dawley Rats exposed to 1 Gy 
56Fe ions; delivery of SeM in diet 3 
days pre-IR; decreased total 
antioxidant status 
FDA approval as 
dietary 
supplement 
Kennedy 2003 
Eusatron and 
Ondansetron (Zofran) 
Anti-Emetic 5-hydroxytryptamine 
(5-HT3) 
serotonin subtype-three receptor 
antagonist 
Ferrets exposed to 2Gy TBI 2-Gy 
doses of either 60Co gamma or 
neutron:gamma, mixed-field 
irradiation; delivery post-IR; mitigated 
emesis 
FDA approved to 
prevent nausea 
and vomiting; 
currently in ISS 
medical kit 
King 1999 
Manganese Superoxide 
Dismutase (MnSOD) 
Radiomitigator Protein Anti-apoptotic; metabolizes 
reactive oxygen species 
CBAxC57Bl6 F1 hybrid SPF mice 
exposed to 4Gy 171MeV 
protons;delivery 6x/day; accelerated  
recovery of thymus and spleen mass 
and of the number of leukocytes in 
mice peripheral blood 
In clinical trial for 
protection of 
radiation 
induced 
esophagitis 
Ambesi-Impiombato 
2014 
Neupogen Radiomitigator Recombinant growth 
factor 
Granulocyte Colony Stimulating 
Factor (G-CSF)  
ICR mice exposed to 0.5, 1 or 2 Gy 
137Cs or SPE-like proton; delivery 1 
day pre-IR, immediately post-IR or 1 
day post-IR; increased neutrophil 
counts 
FDA approval 
under Animal 
Rule for ARS 
Romero-Weaver 
2013 
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Neulasta (pegylated 
form of Neupgen) 
Radiomitigator Pegylated growth factor Granulocyte Colony Stimulating 
Factor (G-CSF)  
Yucatan mini pigs exposed to 2 Gy TBI 
SPE-like protons; temporarily 
alleviates proton radiation-induced 
WBC loss, but has no effect on altered 
hemostatic responses 
NHP studies 
conducted for 
FDA approval to 
treat ARS under 
Animal Rule 
Sanzari 2015 
Cocktail: SeM, α-lipoic 
acid, NAC, sodium 
ascorbate and Vitamin E 
succinate 
Radioprotector Dietary antioxidant 
cocktail 
Anti-apoptotic; reactive oxygen 
species scavengers 
ICR mice exposed to 1 or 7Gy TBI 
137Cs; fed cocktail diet for 7 days pre-
IR; second group began cocktail diet 2 
hr post-IR; no attenuation of 
lymphopenia; attenuated the 
radiation-induced inflammatory 
response and hematopoietic cell 
death 
ICR mice exposed to 1Gy proton; fed 
cocktail diet for 7 days pre-IR; second 
group began cocktail diet 2 hr post-IR; 
improved recovery of peripheral 
leukocytes and platelets 
Research 
ongoing 
Kennedy 2006, 
Wambi 2008, 2009, 
Sanzari 2011 
Fructose Radioprotector 
and mitigator 
monosaccharide Immune modulation; oxidative 
protection  
ICR mice exposed to 2 Gy TBI 137Cs 
gamma or SPE-like proton; delivery of 
fructose daily for 7 days pre-IR 
continuing post-IR or daily for 7 days 
pre-IR; increase the numbers of 
lymphocytes 
No known 
studies ongoing 
Romero-Weaver 
2014 
Enrofloxacin Radiomitigator broad-spectrum orally 
available antibiotic 
Anti-microbial C3H/HeNCr MTV- mice exposed to 
2Gy 137 Cs or SPE-like protons; 
delivery 5 days post-IR 2x/day until 
the end; enhanced bacterial 
clearance and significantly decreased 
morbidity and mortality 
No known 
studies ongoing 
Li 2015 
Mometasone cream 
(Elecon) 
Radiomitigator Corticosteroid Anti-inflammatory; antipruritic; 
vasoconstrictive 
 
Yucatan mini pigs exposed to 5 or 10 
Gy TBI proton; delivered topically 
1x/day and covered with Tegaderm 
post-IR for 14 days; mitigated skin 
toxicity; decreased melanosomes, 
necrotic keratinocytes and melanin 
deposition 
FDA approved 
for psoriasis and 
dermatitis 
Kennedy 2014 
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Benefix  Radiomitigator Recombinant protein 
factor IX 
Replaces the missing clotting factor 
IX that is needed for effective 
hemostasis 
De-scented ferrets exposed to 1Gy 
TBI SPE-like protons;delivery 30 min 
pre-IR; improved clotting values in 
the irradiated ferrets 
FDA approval for 
hemophilia B 
Krigsfeld 2013 
Bowman-Birk Inhibitors 
(BBI) 
Radioprotector 
and mitigator 
Protease inhibitor Antioxidant CBA/JCR HSD exposed to 0.5Gy 56Fe 
ions or 3Gy protons; delivered in food 
3 days pre-IR then daily post-IR; 
reduced yields of neoplastic lesions; 
no impact on survival 
FDA IND Kennedy 2006, 2008 
Blueberry or Strawberry 
Extracts 
Radioprotector Antioxidant Free radical scavenging, 
polyphenols 
Sprague–Dawley rats exposed to 1.5 
Gy of 1 GeV/n 56Fe particles; delivery 
2% blueberry or strawberry extracts 2 
months pre-IR; 2% strawberry extract 
can prevent the disruption of 
responding on an ascending fixed-
ratio operant task 
Research 
ongoing 
Rabin 2005 
Androstenediol (5-AED) Radioprotector 
and mitigator 
Steroid Nuclear Factor-κβ; increases G-CSF 
and IL-6 
C57BL/6J mice exposed to 3Gy 56Fe; 
delivery 30 min post-IR; restored 
hematopoiesis 
FDA IND 
approval 
Loria 2011 
Dragon’s Blood and 
extracts 
Radioprotector Resin from the fruit of 
Daemonorops draco 
tree 
anti-inflammatory; anti-apoptotic  Wistar rats exposed to 2.5Gy whole 
head 12C6+ heavy ions; delivery 1x/day 
for 5 days pre-IR then 1x/day until 
endpoint; decreased 
malondialdehyde and hydrogen 
peroxide levels; increased SOD 
activity and glutathione levels; 
decreased inflammatory cytokines 
Herb; not 
regulated by FDA 
Xin 2012 
Vitamin A acetate 
(retinol acetate) 
Radioprotector Vitamin Anti-inflammatory; MMP inhibitor Sprague-Dawley rats dorsal skin 
exposed to 3Gy 56Fe ions; delivery 1 
week in food pre-IR continuing post-
IR until endpoint; decreased 
expression of immune- and stress-
response genes 
FDA approval as 
dietary 
supplement 
Zhang 2006 
Fish oil and pectin Radioprotector Dietary supplements Inhibition of Notch signaling; anti-
inflammatory 
Sprague–Dawley rats exposed to 1 Gy 
of 1 GeV/n 56Fe particles; delivery of 
fish oil and pectin in diet 3 weeks pre-
IR; suppressed antiapoptotic PPARδ 
levels 
FDA approval as 
dietary 
supplements 
Vanamala 2008 
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α-Lipoic acid  Radioprotector 
and mitigator 
Organosulfur 
compound 
lipophilic antioxidant hippocampal precursor cells exposed 
to 1 Gy of 1 GeV/n 56Fe particles; 
delivery 1 hr pre-IR or 2hr post-IR; 
reduced reactive oxygen species 
Regulated by 
FDA as a dietary 
supplement 
Limoli 2007 
Amifostine (Ethyol) or 
WR-1065, WR-2721, 
WR-151,327 
 
Radioprotector Aminothiol Antioxidant; free radical scavenger; 
DNA protector 
CHO. S31WT clone, MCF10A, and 
SPD8 Chinese hamster cells exposed 
to 2 Gy of X rays; delivery of WR-1065 
with 30 min or 24 hr incubation of 
CM; prevented hyper-recombination 
and mutagenesis 
FDA approval for 
renal toxicity and 
xerostemia in 
patients being 
treated for 
cancer 
Dziegielewski 2010 
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VII. Gaps 
 
Current research is focused on closing the following knowledge gaps: 
 
Acute–1: Determine the dose response for acute effects induced by SPE-like radiation, including 
synergistic effects (focusing on effects that are evident at space-relevant doses) arising from 
other spaceflight factors (microgravity, stress, immune status, bone loss, etc.) that modify 
and/or enhance the biological response. (Note: Acute-1 and Acute-3 were combined into 
Acute-1).     
 
Acute–2: What quantitative procedures or theoretical models are needed to extrapolate molecular, 
cellular, or animal results to predict acute radiation risks in astronauts? How can human 
epidemiology data best support these procedures or models? 
 
Acute–4: What are the probabilities of hereditary, fertility, and sterility effects from space 
radiation? (On hold pending evidence of risk at space relevant exposures) 
 
Acute–5: What are the optimal SPE alert and dosimetry technologies? (Closed. Technology 
maturation transferred to Advanced Exploration Systems)    
 
Acute–6: What are the most effective shielding approaches to mitigate acute radiation risks, how 
do we know, and implement? (Closed. Transferred to Operations) 
    
Acute–7: What are the most effective biomedical or dietary countermeasures to mitigate acute 
radiation risks?         
 
Acute–8: How can probabilistic risk assessment be applied to SPE risk evaluations for EVA, and 
combined EVA+IVA exposures? 
 
The SRPE overlaps with several of the gaps within other HRP Elements as outlined in the HRP 
Integrated Research Plan (IRP).  SRPE works with the other HRP Elements to integrate gaps as 
necessary in accordance with the IRP. 
 
VIII. Conclusion 
 
The biological effects of space radiation, including ARS, are a significant concern for 
manned spaceflight. The primary data that are currently available are derived from analyses of 
medical patients and persons accidentally exposed to high doses of radiation. High doses 
of radiation can induce profound radiation sickness and death. Lower doses of radiation induce 
symptoms that are much milder physiologically but that pose operational risks that may be equally 
serious. Both scenarios have the potential to seriously affect crew health and/or prevent the com-
pletion of mission objectives.  NASA has established short-term dose limits to prevent clinically 
significant deterministic health effects, including performance degradation in flight. Radiation 
protection must be provided in the form of shielding and operational dosimetry and monitoring, 
as well as biological countermeasures (if an unavoidable exposures is encountered), when traveling 
outside of the protective magnetosphere of Earth.  Predictive models support the evaluation of crew 
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risks, operational requirements and decisions, and the efficient design of vehicle shelters to 
minimize exposures.   
As future NASA missions once again extend beyond LEO and now for longer durations, 
radiobiology research is focused on validating the current PELs, as there is reasonable concern 
that a compromised immune system due to high skin doses from a SPE or due to synergistic space 
flight factors (e.g., microgravity) may lead to increased risk to the BFO. Research data specific to 
the space flight environment are being compiled to quantify the magnitude of this increased risk 
and to develop appropriate predictive models and protection strategies. In addition, clinically 
relevant biological countermeasures or those developed for counterterrorism are being identified 
and validated for spaceflight-relevant exposures, which are characterized by different radiation 
qualities and dose rates than those associated with terrestrial applications.   
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IX.  LIST OF ACRONYMS 
 
ARRBOD Acute Radiation Risk and BRYNTRN Organ Dose 
ARS  Acute Radiation Syndrome 
BFO  Blood Forming Organ  
CAF  Computerized Anatomical Female 
CAM  Computerized Anatomical Male 
CME  Coronal Mass Ejection  
CNS  Central Nervous System 
DNA  DeoxyriboNucleic acid  
DoD  Department of Defense  
ED10  Dose at which 10% of the population receive the effect 
EVA  ExtraVehicular Activity 
F   Solar modulation parameter  
FAX  Female Adult voXel mode 
FW  Fatigue/Weakness  
GCR  Galactic Cosmic Rays  
GI   GastroIntestinal  
GOES  Geostationary Operational Environmental Satellite  
Gy   Gray 
Gy-Eq  Gray-equivalent 
HSC  Hematopoietic Stem Cell 
HU  Hindlimb Unloaded 
HZE  High Charge and Energy  
ICRP  International Commission on Radiological Protection  
IL       Interleukin 
IRP  Integrated Research Plan  
IVA  IntraVehicular Activity  
LD50  median Lethal Dose 
LET  Linear Energy Transfer 
MAX  Male Adult voXel model  
MeV  Megaelectron Volt 
mGy  milliGray 
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mSv   milliSievert 
NAS  National Academy of Sciences  
NCRP  National Council on Radiation Protection and Measurements  
NOAA  National Oceanographic and Atmospheric Agency’s  
NRC  Nuclear Regulatory Commission  
NUREG NUclear REGulations from NRC 
PEL  Permissible Exposure Limit 
RBE  Relative Biological Effectiveness  
SPE  Solar Particle Event  
TGF  Transforming Growth Factor 
TNF  Tumor Necrosis Factor 
UGID  Upper Gastro Intestinal Distress 
 
